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ABSTRACT OF DISSERTATION 
 
 
STUDIES TOWARD SYNTHESIS OF POLYCYCLIC POLYPRENYLATED 
ACYLPHLOROGLUCINOLS 
 
Polycyclic polyprenylated acylphloroglucinols (PPAPs) are a class of compounds 
that reveal intriguing biological activities and interesting and challenging chemical 
structures. These products are claimed to possess antioxidant, antiviral, and antimitotic 
properties. Increasing interest is related to their function in the CNS as modulators of 
neurotransmitters associated to neuronal damaging and depression. All these features 
make PPAPs targets for synthesis. We decided to focus our own initial efforts in this area 
on the type A PPAP, nemorosone because we thought that its fairly simple structure 
relative to other PPAPs would present fewer hurdles as we developed our methodology. 
In the past decade many approaches to the synthesis of the bicyclo[3.3.1]nonane-
2,4,9-trione structure of type A PPAPs have been reported, but only two total syntheses 
of any PPAP, garsubellin A by Shibasaki and Danishefsky, have been published recently, 
near the end of 2005.  All approaches have relied on the α,α´-annulation of a three-carbon 
bridge onto a cyclohexanone, although the methods used to execute this annulation differ 
dramatically.  The methods most often used to form the two new C–C bonds have 
involved classical carbonyl chemistry. 
We have developed a short and efficient synthetic approach to the 
bicyclo[3.3.1]nonane skeleton of the PPAPs that involves a novel three-carbon α,α´-
annulation of a sterically hindered cyclic β-keto ester with 3,3-diethoxypropyne. The 
alkynylation reaction permits the construction of the two contiguous quaternary centers 
of the PPAPs in reasonable yield and without complications from side reactions. We have 
also successfully applied a recently developed syn hydrosilylation to the very hindered 
product of this alkynylation reaction. Our methodology received positive feedback 
already, and we see this total synthesis of nemorone as an ideal platform for the 
implementation of new synthetic methodologies. 
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Chapter 1. Introduction to PPAPs 
1.1. Introduction 
In earlier times, all drugs and medicinal agents were derived from natural 
substances.  New drug discovery involved a trial-and-error approach on naturally derived 
materials and substances until the end of the nineteenth century.  The first half of the 
twentieth century witnessed systematic pharmacological evaluations of both natural and 
synthetic compounds.  However, most new drugs until the 1970s were discovered by 
serendipity.  For example, penicillin, the first antibiotic to be discovered, was found by 
chance in 1928 when Alexander Fleming accidentally contaminated a petri dish 
containing bacteria (Staphylococcus aureus) with the mold that produces this antibiotic 
(Penicillium).   
Plants have long been a very important source of drugs, and many plant species 
have been screened to see if they contain substances with therapeutic activity.  For 
example, digoxin from foxgloves (an old discovery) was used to treat heart failure, and 
paclitaxel (discovered in yew bark) is a more recent anticancer agent.   
For many diseases, the current drug repertoire is limited or inadequate, and the 
problem is being further exacerbated by the emergence of drug resistance.  New drugs are 
desperately needed and will continue to be needed for the foreseeable future.   
Depression is a serious disorder that affects roughly 25% of women and 10% of 
men at some point of their lives.  Studies showed that, just in the USA, more than 19 
million adults suffer from depression.  There are three main types of depressive disorders: 
major depressive disorder, dysthymic disorder, and bipolar disorder (manic-depressive 
illness).  The cause of this illness is still unknown, but it is thought to be partly hereditary 
and partly caused by everyday stress.  Throughout the years, depression has affected 
many accomplished people, including Abraham Lincoln, Ernest Hemingway, Peter 
Tchaikovsky, Charles Dickens, Virginia Woolf, and Mary Shelley.  The good news is 
that this mental disorder is treatable in more than 90% cases with the right medication 
and under doctor supervision.   
In recent years, the antidepressant activity of Hypericum perforatum, commonly 
known as St. John’s wort, has attracted much attention from both scientists and the wider 
public.1,2 Investigations of the constituents of St. John’s wort and other plants from the 
family Guttiferae and related families have revealed a class of compounds, polycyclic 
polyprenylated acylphloroglucinols (PPAPs), with fascinating chemical structures and 
intriguing biological activities.  The PPAPs feature a highly oxygenated and densely 
substituted bicyclo[3.3.1]nonane-1,3,5-trione core, to which are attached C5H9 or C10H17 
 1
 
(prenyl, geranyl, etc.) side chains (the latter in several isomeric forms).  The PPAPs can 
be divided into three classes: type A PPAPs have a C(1) acyl group and an adjacent C(8) 
quaternary center, type B PPAPs have a C(3) acyl group, and type C PPAPs have a C(1) 
acyl group and a distant C(8) quaternary center (Figure 1.1).3  (Only a handful of type C 
PPAPs are known.) Secondary cyclizations involving the β-diketone and pendant olefinic 
groups may occur to afford adamantanes, homoadamantanes or pyrano-fused structures.   
 
O
R1
O
R1
HO
O
R3
R1
R2
O
R1R1
OHO
R1
R2
O R3
O
R1
O
R1
HO
R1
R2
O
R3
type A type B type C
R1 = prenyl or geranyl
R2 = H or prenyl
R3 alkyl or aryl
5 5 51 1 1
3 3 3
8 8 8
 
 
Figure 1.1: Type A, B, and C PPAPs 
PPAPs are biosynthetically derived from the less complex monocyclic 
polyprenylated acylphloroglucinols (MPAPs), which are found in many plants from the 
Myrtaceae and Cannabinaceae families, often as dimers.  MPAPs are reported to show 
antimicrobial, antifungal and antifeedant activity.4,5  For example, Humulus lupulus 
(Cannabinaceae), commonly known as hops, is used in folk medicine as an antibacterial 
(in the form of wound powders and salves), a tranquilizer (sleep inducer), a diuretic, and 
to ameliorate the symptoms of menopause.  Perhaps more importantly, the female 
inflorescences (hop cones) of hops are also used in beer production.  Two classes of 
MPAPs are found in hops (Figure 1.2).  The α-acids are converted during the brewing 
process into iso-α-acids, the compounds that are responsible for the flavor and the bitter 
taste of beer.6  The β-acids do not add any taste because of decomposition.  Although β-
acids are not important to the brewing industry, they show radical scavenging activity, 
inhibition of lipid peroxidation, and antimicrobial activity.7  
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OH
O
O
R
HO
HO
OH
O
O
R
HO
 
                                              α-acids                                               β-acids 
 
R α-acids β-acids 
i-Pr cohumulone colupulone 
i-Bu humulone lupulone 
s-Bu adhumulone adlupulone 
 
Figure 1.2: Hops-derived α- and β-acids 
Little is known about the synthesis of these hop acids, most of the studies being 
made in early 1970s.8-10 All the attempts resulted in formation of β-acids and their 
derivatives in very low to moderate yield and no α-acids were obtained.   
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1.2. Survey of PPAPs 
A list with type A, B, and C PPAPs reported and isolated so far is presented in 
Tables 1–3, respectively.  The majority of these compounds are type A and B. Only three 
natural products, garcinelliptones K–M (117–119), are reported to have type C 
structures.11  Nemorosone (5), was classified first as a type C structure,12,13 but its 
structure has since been corrected to a type A structure.3  One may wonder if the three 
structures of garcinelliptones K–M have been correctly determined, because if the two 
bridgehead groups of garcinielliptone K, L, and M are switched, the structures become 
identical to those of hyperibone B,14 garsubellin C, and garsubellin D (29, 32, and 
27),15,16 respectively, and the garsubellins and garcinielliptones are both isolated from 
Garcinia subelliptica.11,15,16  At a closer look, though, the two type C structures of 
garcinielliptones K and M seem to be correctly assigned due to the observation of an 
NOE interaction between the acyl group and one of the H atoms of the ring CH2 group in 
these two compounds.11  Moreover, by examining the NMR spectra of garcinielliptone K 
and hyperibone B, one can observe that they do not match, so it is unlikely that the 
structure of garcinielliptone K has been misassigned and that the two compounds are both 
29.11,14  Unfortunately, we cannot do the same examination of the NMR spectra of the 
garcinielliptones L and M  and garsubellins C and D, respectively to determine whether 
they are identical, because the NMR spectra of the garsubellins were measured in 
C6D6,
15,16 and those of the garcinielliptones were measured in CDCl3.
11  
The stereochemistry of plukenetiones F and G (39 and 41), was assigned by 
Grossman and Jacobs, who have shown that the orientation of the C(7) substituent in 
PPAPs (endo or exo) can be easily determined by examining the 1H and 13C NMR 
spectra of the PPAPs.17  When the C(7) substituent is exo, the difference in chemical 
shifts of the two H(6) atoms is ~0.5 ppm, and the chemical shift of C(7) is 45–48 ppm; 
but when the C(7) substituent is endo, the difference in chemical shifts of the two H(6) 
atoms is ~0.1 ppm, and the chemical shift of C(7) is 41–44 ppm.  Using the same 
technique when examining the stereochemistry of other PPAPs, we noticed that 
hypersampsone F and hyperibones C, E, F, H, and I (42, 35, 20, 21, 101, and 102) have 
endo C(7) substituents, not exo as first proposed.14,18,19 We also noticed, using NMR and 
optical rotation data, that garcinielliptone I is enantiomeric to that of hyperibone A (33), 
not identical to that of hyperibone B (29), as originally proposed.14,20   
Herath21 reports a compound which he calls guttiferone I as having a C(7) endo 
substituent but at a closer look at its NMR data (δ value of C(7) is 41.2 ppm, Δδ value for 
H(8)  is 0.72 ppm, and H(7)–H(8)ax coupling constant is 13.0 Hz) suggest that it is an exo 
compound. Also, he reports that guttiferone I has an NMR spectrum similar to that of 
 4
 
guttiferone G, 97 and concludes that they are different because of their different optical 
rotation values (+8.7° for 98 vs. - 25° for 97). We think that guttiferone I is identical to 
guttiferone G, and one or the other optical rotation reported for this compound is 
inaccurate. The correct structure of guttiferone I has been reported by Nilar.22  
To our knowledge, the only PPAPs whose absolute configurations have been 
determined experimentally are hyperforin,23 xanthochymol,24 and isoxanthochymol24 (1, 
88, and 99).  Some PPAPs (hyperibone G 13 and propolone D 14,14,25 hyperibone A 33 
and garcinielliptone I 34,14,20,25 guttiferone E 84 and garcinol 85,26-31 isoxanthochymol 99 
and isogarcinol 10018,28-33) have been isolated in both enantiomeric forms.  Although we 
chose to draw the C(9) ketone pointing toward the reader, one cannot infer the 
information about absolute configuration of a compound.   
In the Tables, the isogeranyl and ω-isogeranyl groups are defined as in Figure 1.3.   
 
                                              (R)-isogeranyl                      ω-isogeranyl 
Figure 1.3:  Isogeranyl and ω-isogeranyl groups 
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Table 1.1:  Type A PPAPs 
No. Structure Name Sourcea [α]Db 
 
O
R3
O
R4
HO
O
R1
R2
 
   
1 
R1 = i-Pr;  
R2, R3, R4 = prenyl 
Hyperforinc H. perforatum34-36 
+41 (e, 
5) 
2 
R1 =s-Bu;  
R2, R3, R4 = prenyl 
Adhyperforind H. perforatum37 NR 
3 
R1 = i-Pr;  
R2, R3= prenyl; R4 = H 
Hyperevolutin A 
H. revolutum 
Vahl38 
+84.4 (m, 
0.5) 
4 
R1 = s-Bu;  
R2, R3 = prenyl; R4 = H 
Hyperevolutin Bd 
H. revolutum 
Vahl38 
NR 
  5 
R1 = Ph;  
R2 = H;  
R3, R4 = prenyl 
Nemorosone 
Cuban propolis, C. 
rosea, C. 
grandiflora, C. 
insignis, C. 
nemorososa3,12,13,39 
+113 
(0.1);  
OMe: 
+150 (m, 
0.8) and 
+49 (1.4) 
 6
 
6 
R1 = 3-hydroxyphenyl;  
R2 = H;  
R3, R4 = prenyl 
Hydroxynemorosone
e 
C. nemorososa13 
OMe: 
+143 (m, 
0.7) 
7 
R1 = Ph; R2 = H;  
R3 = isogeranyl;  
R4 = prenyl 
Chamone Id C. grandiflora39 NR 
8 
R1 = isopropyl; R2 = H;  
R3 = CH2CH2CMe2OH;  
R4 = prenyl 
Garcinielliptone A G. subelliptica40 –33 (0.6) 
9 
R1 = s-Bu; R2 = H;  
R3 = prenyl;  
R4 = CH2CH2CMe2OH 
Garcinielliptone D G. subelliptica40 –22 (0.1) 
10 
R1 = sec-butyl; R2 = H;  
R3 = prenyl;  
R4 = (E)-CH=CHCMe2OH 
Garcinielliptone F G. subelliptica20 
–23 
(0.09) 
 
O
OHO
O
Ph
X  
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11 X = H Plukenetione D/E 
C. nemorosa, C. 
plukenetii41,42 
OAc: 
+34.5 
(0.03),  
–37.6 
(0.1); 
OMe: 
+10.7 
(3.1) 
12 X = OAc Insignone C. insignis43 
OMe: 
+92.7 
(1.6) 
 
O
O
R2
O
O
R1
X
R3
 
   
13 
R1 = Ph;  
R2 = prenyl;  
R3 = H; X = OH 
Hyperibone G H. scabrum14 
–29.3 
(0.9) 
14 
R1 = Ph;  
R2 = prenyl;  
R3 = H; X = OH 
(enantiomer) 
Propolone D Cuban propolis25 
+48.5 
(0.7) 
 8
 
15 
R1 = Ph;  
R2 = 
CH2CH(OH)CMe=CH2;  
R3 = H; X = OH 
Hyperibone Dd H. scabrum14 
–61.9 
(0.7) 
16 
R1 = i-Pr;  
R2 = prenyl;  
R3 = H; X = OH 
Garsubellin A G. subelliptica15,16 
–21 (e, 
1.1) 
17 
R1 = s-Bu;  
R2 = prenyl;  
R3 = H; X = OH 
Garsubellin Bd G. subelliptica16 
–36 (e, 
0.6) 
18 
R1 = i-Pr;  
R2, R3 = prenyl;  
X = OH 
Furohyperforin H. perforatum44,45 
+62.4 
(0.9), 
+81.9 
(0.9, m), 
+68 (0.2) 
19 
R1 = i-Pr;  
R2, R3 = prenyl;  
X = OOH 
33-Deoxy-33-
hydroperoxy-
furohyperforin 
H. perforatum46 +75 (1.2) 
 9
 
 
O
O
R1
O
O
Ph
R3
HO
R2
 
   
20 
R1 = 
CH2CH(OH)CMe=CH2;  
R2 = H;  
R3 = (E)-CH=CHCMe2OH 
Hyperibone Ed,f H. scabrum14 
–56.0 
(0.2) 
21 
R1 = prenyl; R2 = H;  
R3 = (E)-CH=CHCMe2OH 
Hyperibone Ff H. scabrum14 
–31.0 
(0.2) 
22 R1, R2, R3= prenyl Sampsonione Ke H. sampsonii47 
–5.6 
(1.1) 
23 
R1, R3= prenyl;  
R2 = H 
Sampsonione L H. sampsonii47 
+55 
(0.06) 
24 
O
OO
O
i-Pr
HO
OH
 
Garcinielliptone C G. subelliptica40 –40 (0.2) 
25 
O
OO
O
PhH
 
No name C. obdeltifolia48 
+30.9 
(0.3) 
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26 
O
OO
O
Ph
OH
 
Propolone C Cuban propolis25 
+35.7 
(0.2) 
 O
OO
O
R1
R2
HO
 
   
27 
R1 = isopropyl;  
R2 = prenyl 
Garsubellin D G. subelliptica16 
–12 (e, 
0.4) 
28 
R1 = sec-butyl;  
R2 = prenyl 
Garsubellin E G. subelliptica16 
–7 (e, 
0.4) 
29 
R1 = Ph;  
R2 = prenyl 
Hyperibone B H. scabrum14,25 
–20.8 
(0.5);  
–42.2 
(0.1) 
30 
R1 = 3,4-dihydroxyphenyl;  
R2 = (R)-isogeranyl 
Garcinielliptone FB G. subelliptica49 –66 (0.2) 
31 
O
OO
O
Ph
HO
 
Sampsonione M H. sampsonii47 
+55 
(0.04) 
 11
 
 
O
OO
O
R
HO
 
   
32 R = isopropyl Garsubellin C G. subelliptica15,16 
+39 (e, 
0.4) 
33 R = Ph Hyperibone A H. scabrum14,25 
+57 
(0.2);  
+63.7 
(0.4) 
34 R = Ph (enantiomer) Garcinielliptone Ig G. subelliptica20 
–37.7 
(1.1) 
35 
O
OO
O
Ph
HO
OH  
Hyperibone C H. scabrum14 
–27.3 
(0.3) 
36 
O
OO
O
Ph
 
Chamone IId C. grandiflora39 NR 
 12
 
37 
O
OO
O
Ph
OH
HO OH
 
Propolone Bd Cuban propolis25 
+38.2 
(0.6) 
38 
O
OO
O
Ph
OOH
 
15,16-dihydro-16-
hydroperoxy-
plukenetione F 
C. havetiodes var. 
stenocarpa50 
+24.7 
(0.3) 
 
O
OO
O
R1
R2
 
   
39 R1 = i-Pr; R2 = Me Papuaforin B H. papuanum51 NR 
40 R1 = Ph; R2 = prenyl Scrobiculatone B C. scrobiculata43 
+44.7 
(0.2) 
 
O
OO
O
R1
R3
R2  
   
41 
R1 = Ph; R2 = H; R3 = 
prenyl Plukenetione F
h C. plukenetii41 
–53.6 
(0.03) 
42 R1 = Ph; R2,R3 = prenyl Hypersampsone Ff H. sampsonii52 +30 (0.2) 
 13
 
43 
O
O
O
Ph
O
 
Plukenetione Gh C. plukenetii41 NR 
 
O
O
O
R1
R3
O
R2  
   
44 
R1 = i-Pr;  
R2, R3 = prenyl 
Pyrano[7,28-b]-
hyperforin 
H. perforatum53 
+83.5 
(0.3) 
45 
R1 = Ph;  
R2 = H; R3 = prenyl 
Scrobiculatone A C. scrobiculata43,51 
+44.7 
(0.2) 
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46 
R1 = i-Pr;  
R2 = H; R3 = CH3 
Papuaforin A H. papuanum51 
+13 (0.1, 
m) 
47 
R1 = s-Bu;  
R2 = H; R3 = CH3 
Papuaforin Cd H. papuanum51 
+23 (0.1, 
m) 
48 
R1 = s-Bu;  
R2 = prenyl; R3 = CH3 
Papuaforin Dd H. papuanum51 
+64 (0.1, 
m) 
49 
R1 = i-Pr;  
R2 = prenyl; R3 = CH3 
Papuaforin E H. papuanum51 
+41 (0.1, 
m) 
 
O
O
O
R
O
 
   
50 R = Ph Propolone A Cuban propolis26 +40 (0.1) 
51 R = i-Pr Garcinielliptone B G. subelliptica40 –23 (0.1) 
 
O
O
i-Pr
R
O
O
OH
 
   
52 R = prenyl 
8-
Hydroxyhyperforin-
8,1-hemiacetal 
H. perforatum46 +34 (1.0) 
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53 R = CH3 Hyperibone J H. scabrum
54 
+16.9 
(0.3) 
54 
O
O
i-Pr
O
OHO
 
Oxepahyperforin H. perforatum46 
–73.7 
(0.8) 
 
O
O
O
H
OHO
i-Pr
R
 
   
55 R = prenyl Garcinielliptin oxide G. subelliptica55 +1 (0.3) 
56 R = CH2CH2CMe2OH Garcinielliptone E G. subelliptica
40 –51 (0.2) 
57 
O
O O
O
i-PrHO
HO OH
OH
 
Garcinielliptone H G. subelliptica20 
–14.3 
(0.1) 
58 O
O
i-Pr
O
HO
O
HO
 
Garcinielliptone G G. subelliptica20 –53 (0.1) 
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59 O
O
i-Pr
O
O
 
Garcinielliptone J G. subelliptica20 
–166 
(0.2) 
 
OO
Ph
O
O
R1
R2
 
   
60 
R1 = prenyl;  
R2 = CH=CMe2 
Plukenetione A C. plukenetii56 +1 (0.8) 
61 
R1 = prenyl;  
R2 = (S)-2,2-
dimethyloxiranyl 
28,29-
Epoxyplukenetione A 
C. havetiodes var. 
stenocarpa50 
–4.4 
(1.0) 
62 
R1 = geranyl;  
R2 = (S)-2,2-
dimethyloxiranyl 
Sampsonione J H. sampsonii47 
+1.48 
(0.2) 
63 OO
Ph
O
O
H
OH
 
No name C. obdeltifolia48 
+10.0 
(0.4) 
64 
OO
Ph
O
O
H OH
 
Sampsonione I H. sampsonii47 
+16.88 
(0.1) 
 17
 
 
OO
Ph O
ROH
O
H
 
   
65 R = geranyl Sampsonione A H. sampsonii57 –49 (0.4) 
66 R = prenyl Sampsonione B H. sampsonii57 NR 
 
OO
Ph O
R O
O
O
OH
H
 
   
67 R = prenyl Plukenetione C C. plukenetii41,50 
+65.9 
(0.1) 
68 
R = (E)-
CH=CHCMe2OOH 
33-hydroperoxy-
isoplukenetione C 
C. havetiodes var. 
stenocarpa50 
–3.9 
(0.2) 
 
OO
R1 O
R2 O
H
R3
 
   
69 
R1 = Ph; R2 = prenyl;  
R3 = CMe2OH 
Plukenetione B C. plukenetii41 
+17.2 
(0.03) 
70 
R1 = Ph; R2 = geranyl;  
R3 = i-Pr 
Hypersampsone D H. sampsonii52 –35 (0.2) 
71 
R1 = i-Pr; R2 = geranyl;  
R3 = CMe=CH2 
Hypersampsone A H. sampsonii52 +21 (0.3) 
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72 
R1 = Ph; R2 = geranyl;  
R3 = CMe2OH 
Sampsonione C H. sampsonii58 +13 (0.2) 
73 
R1 = Ph; R2 = geranyl;  
R3 = isopropenyl 
Sampsonione D H. sampsonii58 +12 (0.2) 
74 
R1 = Ph; R2 = geranyl;  
R3 = O (ketone) 
Sampsonione E H. sampsonii58 
+57.7 
(0.03) 
75 
R1 = Ph; R2 = geranyl; R3 
= H 
Sampsonione H H. sampsonii58 
+5.2 
(0.07) 
 
OO
Ph O
R O
H
OH
 
   
76 R = geranyl Sampsonione F H. sampsonii58 
+14.5 
(1.1) 
77 R = prenyl Sampsonione G H. sampsonii58 
+10.0 
(0.01) 
 
OO
R1 O
O
H
R2
 
   
78 R1, R2 = i-Pr Hypersampsone B H. sampsonii52 +12 (0.3) 
79 R1 = i-Pr; R2 = H Hypersampsone C H. sampsonii52 
+14.3 
(0.2) 
 19
 
80 R1 = Ph; R2 = i-Pr Hypersampsone E H. sampsonii52 +39 (0.2) 
aC. = Clusia, G. = Garcinia, H. = Hypericum.   
bOMe or OAc indicates the specific rotation was measured for that derivative.  The 
values in parentheses are the concentration and the solvent (e = EtOH, m = MeOH, no 
indication = CHCl3).  NR = not reported.   
cThe absolute configuration is known to be as shown.   
dThe positions of the two bridgehead groups have been swapped from where they were 
placed in the original literature reports;12,13 
eNot all the stereocenters’ configurations have been assigned.   
fThe stereochemistry of the C(7) substituent has been reassigned on the basis of the NMR 
spectra;17 see the text.   
gThe originally assigned relative configuration20 has been corrected. 
hThe stereochemistry was assigned by the method of Grossman and Jacobs.17  
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Table 1.2: Type B PPAPs 
No. Structure Name Sourcea [α]Db 
 
O
R1R3
OHO
R2O
R4
 
   
 
81 
R1 = 3,4-(HO)2C6H3;  
R2, R3, R4 = prenyl 
Guttiferone A 
S. globulifera, G. 
livingstonei, G. 
humilis28,59 
+34 (1.7) 
 
82 
R1 = 3,4-(HO)2C6H3;  
R2, R4 = prenyl;  
R3 = -isogeranyl 
Guttiferone Cc S. globulifera 
as mix 
with 83: 
+92 (0.9) 
 
83 
R1 = 3,4-(HO)2C6H3;  
R2, R4 = prenyl;  
R3 = isogeranyl 
Guttiferone Dc S. globulifera 
as mix 
with 82: 
+92 (0.9) 
 
84 
R1 = 3,4-(HO)2C6H3;  
R2 = prenyl;  
R3 = (S)-isogeranyl;  
R4 = H 
Guttiferone E 
Cuban propolis, C. 
rosea, G. 
ovafolia26-28 
+101 
(0.5) 
 21
 
 
 
85 
R1 = 3,4-(HO)2C6H3;  
R2 = prenyl;  
R3 = (S)-isogeranyl;  
R4 = H 
(enantiomer) 
Garcinol (camboginol) 
G. cambogia, G. 
indica29-31 
–138 
(0.1) 
 
86 
R1 = 3,4-(HO)2C6H3;  
R2 = prenyl;  
R3 = (R)-isogeranyl;  
R4 = H 
Guttiferone F 
Allanblackia 
stuhlmannii60 
–293 
(0.4) 
 
87 
R1 = 3,4-(HO)2C6H3;  
R2 = prenyl;  
R3 = geranyl; R4 = H 
Guttiferone Ie G. griffithii22 –68 (1.2) 
 
 
 
88 
R1 = 3,4-(HO)2C6H3;  
R2 = prenyl;  
R3 = (S)--isogeranyl;  
R4 = H 
Xanthochymolf 
Cuban propolis, G. 
xanthochymus, G. 
mannii, G. 
staudtii, G. 
subelliptica, 
Rheedia 
madrunno18,24,26,27,3
3,61-63 
+138 
(0.1) 
89 R1 = CH3; R2 = Ph;  
R3 = prenyl; R4 = H 
Hyperibone L H. scabrum54 
+69.5 
(0.2) 
90 R1 = CH3; R2 = i-Pr;  
R3 = prenyl; R4 = H 
Hyperpapuanone H. papuanum51 
+15 (0.1, 
m) 
 22
 
91 R1, R3 = prenyl;  
R2 = Ph; R4 = H 
7-epi-Clusianone 
C. sandinensis, C. 
torresii64-67 
+62.3 
(1.1) 
 
92 
R1 = CHPhCH2CO2H;  
R2 = i-Bu;  
R3 = prenyl; R4 = H 
Laxifloranonec Marila laxiflora68 
+23.6 
(m, 0.8) 
 
O
R2R3
R4
OHO
R1O
R5
 
   
 
 
 
 
93 R1 = 3,4-dihydroxyphenyl;  
R2, R3, R4 = prenyl;  
R5 = H 
Aristophenoned 
G. 
xanthochymus18,19 
+58 
(0.1);  
OAc: 
+53 
(0.1), 
+54 (0.1) 
 
 
94 R
1 = Ph;  
R2, R3, R4 = prenyl;  
R5 = H 
Clusianoneg 
C. congestiflora, 
C. spiritu-santesis, 
C. torresii13,66,69 
+58.3 
(0.7) 
OMe: 
+61 (1.4) 
 
 
95 
R1 = Ph;  
R2, R4 = prenyl;  
R3 = isogeranyl;  
R5 = H 
Spiritonec 
C. spiritu-
sanctensis69 
NR 
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96 
R1 = 3,4-dihydroxyphenyl;  
R2 = prenyl;  
R3, R4 = geranyl; R5 = H 
Guttiferone B S. globulifera28 –44 (0.5) 
 
 
97 
R1 = 3,4-dihydroxyphenyl;  
R2, R3, R5 = prenyl;  
R4 = geranyl 
Guttiferone G 
G. humilis, G. 
macrophylla21,59 
–25 
(0.04) 
 
O
OO
O
OH
OH
R
 
   
 
98 
R = prenyl Isogarcinol (cambogin)g 
G. indica, G. 
cambogia, G. 
pedunculata29-
31,61,63 
–224 (m, 
0.1) 
 
99 R = prenyl 
(enantiomer) 
Isoxanthochymolf 
G. pyrifera, G. 
subelliptica, G. 
xanthochymus, G. 
ovafolia18,28,32,33 
+181 (e, 
0.6) 
 
100 
R = CH2CH2CMe=CH2 Cycloxanthochymol 
G. pyrifera, G. 
subelliptica32,33 
as 2:3 
mix with 
72: +158 
(m, 0.1) 
 24
 
 
O
R
OO
PhO
OH
 
   
101 
R = (E)-CH=CHCMe2OH Hyperibone Hd H. scabrum
14 
+12.4 
(0.4) 
102 
R = prenyl Hyperibone Id H. scabrum14 
+13.3 
(0.3) 
 
 
103 
O
OHO
O
OH
OH
 
Guttiferone Hc,h G. xanthochymus18 
+94 
(0.006) 
 
 
 
104 
O
OHO
i-PrO
OH
CH3
 
Enaimeone A H. papuanum70 
+27.8 
(0.1, m) 
 
O
OHO
RO
OH
CH3
 
   
105 
R = i-Pr Enaimeone B H. papuanum70 
+29.4 
(0.1, m) 
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106 
R = s-Bu Enaimeone Cc H. papuanum70 
+32.9 
(0.1, m) 
 
O
OHO
R1O
H3C
H
R2
 
   
107 R1 = i-Pr;  
R2 = CMe=CH2 
Ialibinone A H. papuanum71 –22 (0.1) 
108 R1 = s-Bu;  
R2 = CMe=CH2 
Ialibinone Cc H. papuanum71 –26 (0.1) 
109 R1 = i-Pr;  
R2 = CMe2OH 
1´-Hydroxyialibinone A H. papuanum70 
+3.7 
(0.1, m) 
 
O
OHO
R1O
H3C
H
R2
 
   
110 R1 = i-Pr;  
R2 = CMe=CH2 
Ialibinone B H. papuanum71 –91 (0.1) 
111 R1 = s-Bu;  
R2 = CMe=CH2 
Ialibinone Dc H. papuanum71 –72 (0.1) 
112 R1 = i-Pr;  
R2 = CMe2OH 
1´-Hydroxyialibinone B H. papuanum70 
–35.7 
(0.1, m) 
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113 R1 = s-Bu;  
R2 = CMe2OH 
1´-Hydroxyialibinone 
Dc 
H. papuanum70 
–30.3 
(0.1, m) 
 
 
114 O
OHO
i-PrO
H3C
H  
Ialibinone E H. papuanum71 –33 (0.1) 
 
 
115 
HO O
O
OH
OH
O
 
Gambogenonec G. xanthochymus18 
–5 
(0.003, 
m) 
 
 
116 
O O
O O
Ph
 
Hyperibone K H. scabrum54 
+22.3 
(0.3) 
aC. = Clusia, G. = Garcinia, H. = Hypericum, S. = Symphonia.   
bOMe or OAc indicates the specific rotation was measured for that derivative.  The 
values in parentheses are the concentration and the solvent (e = EtOH, m = MeOH, no 
indication = CHCl3).   
cNot all the stereocenters’ configurations have been assigned.   
dThe stereochemistry of the C(7) substituent has been reassigned on the basis of the 
NMR spectra; see the text.17   
eTwo different compounds reported almost simultaneously have both been named 
guttiferone I.21,22   
fThe absolute configuration is known and is opposite to what is shown.   
gThe absolute configuration is known to be as shown.   
hThe stereochemistry of the C(9) bridge relative to the C(6) and C(7) substituents has 
been assigned on the basis of the H(6)–H(7) coupling constant; see the text.17 
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Table 1.3: Type C PPAPs 
No. Structure Name Sourcea [α]Db 
 O
OO
O
R
HO
 
   
117 R = Ph Garcinielliptone K G. subelliptica11 
+27 
(0.3) 
118 R = isopropyl Garcinielliptone M G. subelliptica11 
+73 
(0.2) 
119 O
OO
O
i-Pr
HO
 
Garcinielliptone L G. subelliptica11 
–41 
(0.3) 
aG. = Garcinia.   
bThe values in parentheses are the concentrations (solvent is CHCl3).   
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1.3.  Biological activity of PPAPs 
In this section, the PPAPs that have been shown to have some biological activity 
are discussed.  Many PPAPs have been found to possess moderate antioxidant, antiviral, 
or antimitotic properties.  Increasing interest is related to their function in the CNS as 
modulators of neurotransmitters associated to neuronal damaging and depression.   
1.3.1.  Type A PPAPs 
1.3.1.1.  Hyperforin 
Hyperforin (1a/1b, Figure 1.4), a type A PPAP, is thought to be responsible for 
much of the antidepressant activity of Hypericum perforatum (St. Johns’ wort).72  In vitro 
studies showed that hyperforin (at concentrations of 0.1–1.0 µM) inhibited the 
synaptosomal uptake of many neurotransmitters (see below), but it is still unclear if this 
mechanism is active in vivo.73-75  The ancient Greeks used St. John’s wort for its 
antidepressive properties as well as for treatment of skin injuries, burns, and neuralgia.  
In modern times, it has become very famous as a treatment for mild depression, anxiety, 
and schizophrenia.  Clinical studies have shown St. John’s wort to be as effective as a 
conventional synthetic antidepressant for treatment of mild to moderate depression.76  Its 
mechanism of action has been attributed to its ability to inhibit synaptosomal uptake of 
several neurotransmitters, including serotonin, dopamine, norepinephrine, γ-aminobutyric 
acid (GABA), and L-glutamate, when concentrations become low (IC50 = 1.1 µg/mL).
77  
Serotonin, dopamine, and norepinephrine balance mood and emotion, and GABA 
decreases anxiety and increases relaxation.  By inhibiting the reuptake of these 
neurotransmitters, hyperforin increases their levels in the neural synapses, reinstates 
emotional balance, and improves mood.  Hypericum perforatum reveals not only 
antidepressant activity but also some side effects like nausea, rash, fatigue, restlessness, 
photosensitivity, and acute neuropathy.78 
O
OHO
O
i-Pr
O
OHO
O
i-Pr
1a 1b  
Figure 1.4:  Hyperforin 
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Hyperforin has also long been known to have antibacterial activity.36,75,79,80  A 
recent report on inhibition of penicillin-resistant and methicillin-resistant S. aureus has 
increased the interest in hyperforin as an antibacterial agent.81   
Beside all these positive effects of hyperforin, this natural product can repress 
some other drugs’ effectiveness.82  A recent study has shown that, when patients took St. 
John’s wort together with the asthma drug theophylline, the anticlotting drug warfarin, 
birth control pills, or the immunosuppressant cyclosporine, the blood concentration levels 
of the latter drug decreased drastically.  Hyperforin is a ligand for the pregnane X 
receptor, which regulates the expression of cytochrome P450, an enzyme involved in the 
oxidative metabolism of the above mentioned drugs.82,83  One should be alert to the side 
effects of herbal medicines and always make sure that the efficacy of prescribed drugs is 
not diminished by use of folk medicines.   
Pure, isolated hyperforin is susceptible to oxidation. The instability of hyperforin 
can be attributed to its β-hydroxy enone functionality, which is susceptible to air 
oxidation.  The oxidation products differ depending on the nature of the oxidant, the 
solvent, and the type of hyperforin used (ammonium salt or free acid form).84  If 
hyperforin is treated with peroxidic reagents, the main organic product is the hemiacetal 
52, formed possibly through a C(3)-hydroxylated intermediate (Figure 1.5).  When 
nonperoxidic reagents are used, a mixture of products is formed, the main ones being 
furan and pyran derivatives, 120 and 44, respectively.   
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O
O
i-Pr
O
O
OH
O
O
O
i-Pr
O
O
O
O
i-Pr
O
52 120
44  
Figure 1.5:  Products of oxidation of hyperforin 
As is true of many β-hydroxy enones, hyperforin may be O- or C-alkylated when 
treated with an alkylating agent (Figure 1.6).84,85  O-Methylation occurred when 
hyperforin was treated with methanol under Mitsunobu conditions or with diazomethane, 
whereas C-methylation occurred when hyperforin was treated with MeI.   
 
O
OMeO
O
i-Pr
O
OO
O
i-Pr
Me
 
Figure 1.6:  O- and C-methylhyperforin 
A variety of acylated, alkylated, and oxidized derivatives of hyperforin were the 
subject of structure–activity studies.84  All derivatives studied were less potent than 
hyperforin in their inhibition of neurotransmitter uptake, with IC50 values >10 µg/mL.  
These results are in accordance with the findings of other authors that suggest that 
removing the β-hydroxy enone group of hyperforin dramatically reduces its biological 
activity.45,46,53  The mechanism of action of hyperforin and its derivatives is not fully 
understood, and more studies are required to determine structure–activity relationships in 
this class of compounds. 
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Hyperforin has also recently been found to induce apoptosis in ten human and 
seven rat cancer cell lines, with IC50 values of 3–15 µM,
81 and in K562 and U937 
leukemia cells, LN229 brain glioblastoma cells, and normal human astrocytes, with GI50 
values of 14.9–19.9 µM.86 Hyperforin together with hypericin, a natural product also 
isolated from H. perforatum, synergistically exert a growth inhibitory effect on K562 and 
U937 leukemia cells that is much larger than either compound exerts individually (2.0 
µM 1, 6.0% and 2.1%; 10.0 µM hypericin, 22.3% and 0.6%; combined, 43.6% and 
20.2%).86 
A mixture of hyperevolutin A and a small amount of hyperevolutin B (3 and 4) 
has been found to inhibit the growth of Co-115 colon tumor cells with an ED50 value of 2 
µM.38 
1.3.1.2.  Nemorosone 
Nemorosone (5), another type A PPAP, is found in the resins and latex of plants 
of Clusia (Clusiaceae) species.39  Bees use these resins and latex to build their hives, at 
least partly because they make a good construction material for sealing openings in the 
hive and hardening the cell walls.39  Propolis, an extract of beehives, has been known 
since ancient times as an antiseptic; in fact, Aristotle himself urged people to use it as a 
means to treat abscesses and wounds.87  Studies on bee behavior have revealed that after 
bees kill heavy intruders, they cover them with propolis! Not being able to throw the 
corpses off the hives, the bees make sure that their nest will not develop a bacterial 
infection.   
A large portion of the constituents of propolis are derived from plants.  There are 
over 200 chemical substances in propolis,88,89 their ratio depending on the region from 
which the propolis is collected.  In Europe, the major biological active constituents are 
flavonoids and cinnamic acid derivatives, whereas in tropical regions, the home of many 
Clusia plants, the major compounds are polyprenylated benzophenones such as PPAPs.27  
Despite the differences in their chemical composition, propolis samples from various 
geographical regions have always been found to be biologically active.27   
Nemorosone is the major constituent of Clusia species resin that is responsible for 
its antimicrobial activity, constituting about 50% of the resin by mass.12,13  When a crude 
extract of Clusia species resin is methylated, O-methylnemorosone, 16-
hydroxymethylnemorosone, and 7-epi-methylnemorosone (O-methylplukenetione D/E) 
are obtained.12,13  Cuesta–Rubio has corrected the type C PPAP structure initially 
proposed for nemorosone12,13 to 5 (Figure 1.7) and its tautomer by switching the 
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originally assigned positions of the groups at the bridgeheads.3  Cuesta–Rubio has also 
shown that the structure of O-methylnemorosone is 121.   
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Figure 1.7:  Nemorosone, O-methylnemorosone, and chamone II  
The bactericidal activities of both 5 and 121 were studied, but the latter was not 
active.27,39  The conclusion was that the enol form was necessary for nemorosone to be 
biologically active.  Even the prenylation pattern proved to be essential for the 
antimicrobial effect of this type of natural products, as chamone II (36) was less effective 
than 5 as a bactericide against Paenibacillus honeybee pathogens.   
Besides antimicrobial activity, nemorosone showed cytotoxicity and antioxidant 
activity.27  The IC50 values of nemorosone against four cancer cell lines (3.3–7.2 µM) 
were comparable to those of doxorubicin.  Nemorosone also targets DNA topoisomerases 
and telomerase, but to a much lower extent, the required concentration being 10 to 38 
times higher than that necessary for a 50% inhibition of cellular growth.  Compound 121 
showed much lower cytotoxic and antioxidant activities, the IC50 values being 10–30 
times and 10 times higher, respectively, with respect to that of the reference.   
Nemorosone showed an EC50 of 0.8 µM against HIV infection of C8166 human 
T lymphoblastoid cells.66   
1.3.1.3.  Garsubellin A   
Garsubellin A (16, Figure 1.8) has been isolated from Garcinia subelliptica, a tree 
that grows in Okinawa.16  Studies have shown garsubellin A to be an inducer of choline 
acetyltransferase (ChAT) in P10 rat septal neuron cultures, increasing it by 154% at a 10 
µM concentration.15  Acetylcholine is a neurotransmitter, and a low concentration of this 
compound is associated with neurodegenerative diseases like Alzheimer’s disease.  
Garsubellin A also inhibits the release of β-glucuronidase and histamine, the 50% 
inhibition concentration (IC50 = 15.6 µM) being even lower than that of the reference 
mepacrine (IC50 = 20.6 µM).
40  This property is associated with antiinflamatory activity.  
Other phloroglucinol derivatives isolated from the same plant (garcinielliptones A–D, F, 
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H, I, K–M) show little or no such activity.11,20  The idea that garsubellin A might have 
potential for the treatment of Alzheimer’s disease has led to an increased interest over the 
past decade in studying the biological activity of and possible synthetic approaches90,91 to 
this class of compounds.   
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Figure 1.8:  Garsubellin A 
1.3.1.4.  Other type A PPAPs   
Propolone A (50), 7-epi-clusianone (91), and clusianone (94) (Figure 1.9) were 
tested for their activity against HIV infection of C8166 human T lymphoblastoid cells.66  
Propolone A showed the best results, with an EC50 of 0.32 µM, followed by 7-epi-
clusianone, with EC50 of 2.0 µM.  Clusianone was very active (EC50 = 0.02 µM), but it 
also showed increased cytotoxicity.  The absence of a free enol in propolone A showed 
that this group was not essential to antiviral activity.  Also, the different EC50 values of 
the two epimers, 7-epi-clusianone and clusianone, showed that the C(7) configuration 
was important to the PPAP’s potency.   
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Figure 1.9:  Propolone A, 7-epi-clusianone, and clusianone  
Propolone A also showed antibacterial activity against two Gram-positive bacteria 
(Streptomyces chartrensis and Streptomyces violochromogenes), but it was not active 
toward Gram-negative bacteria and yeasts.26   
In a different study, 7-epi-clusianone exhibited high in vitro activity against 
Trypanosoma cruzi, the microbe responsible for Chagas’ disease, with an LC50 = 260 
µM, 29 times higher than that of the drug used to treat this disease.64  Unfortunately, it 
was inactive in in vivo studies in the mouse model.  More studies with related natural or 
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synthetic compounds are needed to find more active derivatives that could be used as 
chemoprophylactic agents.   
Hyperibone J (52), a hyperforin analog very close in structure to hemiacetal 51, 
showed moderate cytotoxicity against breast and lung tumor cells (IC50 = 17.8 µg/mL 
and >20 µg/mL, respectively).54   
Papuaforins A (46), B (39), and C–E (47–49), which are extracted from 
Hypericum papuanum (Papua New Guinea), show moderate cytotoxic activity against the 
KB cell line (IC50 = 4.9–13.0 µg/mL) and weak antibacterial activity toward three 
bacteria (Micrococcus luteus, Staphylococcus epidermis, and Bacillus cereus).   
1.3.2.  Type B PPAPs 
1.3.2.1.  Garcinol and its derivatives 
Garcinol (85, Figure 1.10),31 also known as camboginol, is extracted from 
Garcinia indica and several other plants as a yellow pigment.29,32,92  The dried fruit rind 
is used in folk medicine and as a garnish for curry in India.  Garcinol shows antibiotic 
activity,32 scavenging activity for 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radical 
(three times more effective than DL-α-tocopherol), hydroxyl radical (more effective than 
DL-α-tocopherol), methyl radical, and superoxide anion.93,94  These results suggest that 
garcinol can play an important role in treatment of gastric ulcer caused by the hydroxyl 
radical95,96 or by a chronic infection with Helicobacter pylori, a global pathogen, which, 
together with cells from gastric mucous membrane, produces hydroxyl radicals and 
superoxide anions.97  Nowadays, antibiotics like clarithromycin are used to treat H. pylori 
infection, but there are some side effects when using antibiotics, such as the development 
of resistance.  Garcinol may be a viable alternative to conventional antibiotics.   
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Figure 1.10:  Garcinol (camboginol) 
Sang et al. has recently reported the structure of some oxidation products of 
garcinol and has proposed mechanisms for the formation of these products (Scheme 
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1.1).98,99  The reaction of garcinol with AIBN or the stable free DPPH radical generates 
the conjugated radical 123.  Cyclization then occurs, involving the catechol ring or a 
pendant alkenyl group to give both compounds known to occur naturally (isogarcinol, 98) 
and those that have not (yet) been isolated from natural sources (124–126).  Isogarcinol 
shows biological activities similar to garcinol; it has been claimed to be an 
antiinflammatory and antitumor compound, a lipase inhibitor, an antiobesity agent, and 
an antiulcer agent.98  It also inhibits the growth of methicillin-resistant S. aureus.   
Garcinol, together with compounds 125 and 126, proved to have good antitumor 
activity, being more effective than curcumin, a well-known antioxidant used as a 
reference in these studies.  The possible chemotherapeutic property of garcinol was also 
tested on other cell lines (human leukemia HL-60 cells, human promyelocytic HL-60 
cells, murine macrophage RAW 264.7 cells, and cyclin D1-positive cells), and the same 
positive effect was obtained.100-102  It inhibits histone acetyltransferases (HATs, IC50 ≈ 7 
µM) and p300/CPB-associated factor (PCAF, IC50 ≈ 5 µM), both of which modulate 
gene expression.  If HAT and/or HDAC (histone deacetylase) activities are altered, 
diseases like cancer or neurodegenerative disease can develop.103   
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Scheme 1.1:  Oxidation pathways of garcinol.   
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1.3.2.2.  Guttiferones A–E, xanthochymol, and their analogs  
Xanthochymol (88) and guttiferone E (84) (Figure 1.11) are extracted as a 
mixture from Garcinia and Clusia species33,60,62 and are said to be inseparable.28  This 
mixture has a strong inhibitory activity against tubulin depolymerization in vitro (IC50 = 
20 µM), comparable to that of paclitaxel (IC50 = 0.5 µM), making it a possible inhibitor 
of cell replication.  However, if the β-hydroxy enone or both phenolic OH groups are 
methylated, or if the double bonds are hydrogenated, a complete loss of activity is 
observed.33  Some activity is retained if only one phenolic OH group is methylated.  
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Unfortunately, the mixture shows no effect on whole cells, suggesting that it cannot cross 
the cell membrane or is deactivated by cellular processes.  Xanthochymol also shows 
antibiotic activity against methicillin resistant Staphylococus aureus32 and inhibit 
topoisomerases I and II.104 
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Figure 1.11:  Xanthochymol and guttiferone E 
Guttiferones A, B, E, C, and D (81, 96, 84, 82, and 83) (Figure 1.12), the latter 
two isolated as an inseparable mixture, were tested for anti-HIV biological activity.28  All 
showed inhibitory effects on in vitro infection in human lymphoblastoid CEM-SS cells, 
with EC50 values of 1–10 µg/mL, but there was no indication of a decrease in indices of 
viral replication.  In a different study, guttiferone F (86) showed both cytoprotection 
against HIV-1 in vitro (EC50 = 23 µg/mL) and cytotoxicity to the host cells (IC50 = 82 
µg/mL).60   
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Figure 1.12:  Guttiferones A, B, C, and D 
Guttiferone E, xanthochymol, aristophenone (93), isoxanthochymol (99) and 
cycloxanthochymol (100) (Figure 1.13) exhibit cytotoxic activity against SW-480 colon 
cancer cells (IC50 = 7.5–33.3 µM) and antioxidant activity in the DPPH free radical assay 
(IC50 = 53–125 µM).
18   
Guttiferone I (87) (Figure 1.13) inhibits the binding activity of α-liver X receptor 
(LXRα) but is less effective against β-receptor (LXRβ), with IC50 = 3.4 µM and >15 µM, 
respectively.21  LXR agonists are therapeutical agents for the control of plasma 
cholesterol levels, increasing reverse cholesterol transport.   
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Figure 1.13:  Aristophenone, isoxanthochymol, cycloxanthochymol, and  
                      guttiferone I 
1.3.2.3.  Ialibinones A–E and analogs 
Ialibinones A–E (107, 110, 108, 111, and 114) (Figure 1.14) were isolated from 
Hypericum papuanum.71  When tested for antibacterial activity, ialibinones C and D 
showed stronger activity than ialibinones A and B against Bacillus cereus and 
Staphylococcus epidermis but almost identical effectiveness against Micrococcus luteus.  
Ialibinone E was ineffective regardless of the bacteria used in the experiment.   
The dried aerial parts of Hypericum papuanum are traditionally used as a remedy 
for sores and wounds due to their antibacterial activity.  The active components of this 
plant are hyperpapuanone, 1´-hydroxyialibinones A, B, and D, and enaimeones A–C (90, 
109, 112, 113, and 104–106) (Figure 1.15).51,70  1´-Hydroxyialibinones A, B, and D show 
identical or slightly reduced antibacterial acivity compared with the ialibinones A, B, and 
D, whereas hyperpapuanone has moderately potent antibacterial activity against 
Micrococcus luteus, Staphylococcus epidermis, and Bacillus cereus.  The cytotoxicities 
of the 1´-hydroxyialibinones are three to five times weaker than that of the corresponding 
ialibinones.  Enaimeones A–C have antibacterial activity similar to ialibinones A–C, but 
show a rather weak cytotoxicity against KB cells.   
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Figure 1.14:  Ialibinones A–E 
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Figure 1.15:  Hyperpapuanone, 1´-hydroxyialibinones A, B, and D, and  
                       enaimeones A–C  
1.3.2.4. Other type B PPAPs 
Laxifloranone (92) (Figure 1.16) exhibits moderate inhibition of the cytopathic 
effects of HIV-1 in a human T-lymphoblastoid cell line (CEM-SS, EC50 = 0.62 µg/mL 
and IC50 = 6.6 µg/mL).
68  Hyperibones K and L (116 and 89) moderately inhibit breast 
(IC50 = 10.0 µM and 15.0 µM, respectively) and lung (IC50 = 13.7 µM and 9.2 µM, 
respectively) tumor cell replication, but they show no anti-HIV activity.54   
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Figure 1.16:  Laxifloranone and hyperibones K and L  
1.3.3.  Type C PPAPs 
Garcinielliptones L (119) and M (119) (Figure 1.17), isolated from Garcinia 
subelliptica, inhibit the release of β-glucuronidase and histamine (119: IC50 = 22.9 and 
>30 µg/mL; 118: IC50 = 13.6 and 19.0 µg/mL), activity which makes them potential 
antiinflammatory agents.11  Mepacrine, a positive control, has corresponding IC50 values 
of 13.6 and 23.3 µg/mL.  The two garcinelliptones also have inhibitory effects on the 
accumulation of NO2– in the culture of RAW 264.7 and N9 cells and slight inhibitory 
effects on tumor necrosis factor α production in cultured RAW 264.7 cells.  
Garcinielliptone FB, isolated from the same plant, shows moderate cytotoxic activity 
against liver, breast and colon cancer cell lines (IC50 = 6.8, 6.3, and 11.2 µg/mL, 
respectively).49   
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Figure 1.17:  Garcinielliptones L and M  
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1.4.  Biosynthesis of PPAPs 
Early labeling experiments provided evidence for a polyketide-type biosynthesis 
for bitter acids which involves one acyl-CoA and three malonyl-CoA units (Scheme 
1.2).76,105-107  Similarly, numerous enzymological studies showed that the biosynthesis of 
acylphloroglucinols involves condensation of three molecules of malonyl-CoA and one 
molecule of acyl-CoA.  The product, a tetraketide, is subsequently cyclized by 
Dieckmann condensation into an acylphloroglucinol.108,109  The prenylation or 
geranylation of this compound occurs through an enzyme-catalyzed addition of prenyl or 
geranyl pyrophosphate to the phloroglucinol moiety.6,110-114   
Scheme 1.2:  Biosynthesis of MPAPs.   
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Cuesta–Rubio proposed that MPAPs are cyclized to both type A and type B 
PPAPs via a common precursor (Scheme 1.3).3  Attack of one of the geminal prenyl 
groups of an MPAP on prenyl pyrophosphate gives the tertiary carbocation 127.  Attack 
of C(1) of 127 on the pendant carbocation (or the corresponding pyrophosphate) would 
provide a type A PPAP, whereas attack of C(5) would provide a type B PPAP.  
Moreover, a single diastereomer of 127 can lead to either a type A PPAP with an exo 7-
prenyl group or a type B PPAP with an endo 7-prenyl group.  A majority of type A 
PPAPs have exo 7-prenyl groups, and most type B PPAPs have endo 7-prenyl groups.  A 
similar mechanism is proposed for hyperforin biosynthesis.76  The most likely scheme for 
the biosynthesis of the type C PPAPs, by contrast, would require that the initial MPAP 
have its quaternary center bear the acyl group (Scheme 1.4).   
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Scheme 1.3:  Cyclization of MPAPs to give type A or B PPAPs.   
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Scheme 1.4:  Possible biosynthesis of type C PPAPs.   
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Chapter 2.  Synthetic efforts toward PPAPs 
In the past decade many papers on the approaches to the synthesis of the 
acylbicyclo[3.3.1]nonane-2,4,9-trione structure of type A PPAPs have been published, 
but only two total syntheses of any PPAP, garsubellin A, have so far been reported by 
Shibasaki and Danishefsky90,91 at the end of 2005. All approaches, with no exception, 
were linear. Linear synthesises have the drawback not only of an overall low yield but 
also of devoting a large amount of time to the process of converting starting material into 
the final product through numerous steps. Although a convergent synthetic protocol 
would always be desirable, it was hard to apply such methods in the case of these 
topological complex molecules. From a synthetic point of view, one can notice that all 
approaches have relied on the α,α´-annulation of a three-carbon bridge onto a 
cyclohexanone. The methods most often used to form the two new C–C bonds have 
involved classical carbonyl chemistry.  Shibasaki’s first approach used an addition–
elimination with a β-chloroacrylate derivative followed later by an aldol reaction,115,116 
Stoltz used a Claisen–Dieckmann reaction with malonyl chloride,117 Kraus used two 
addition–elimination reactions with a diacetoxyvinyl sulfone,118 and Nicolaou used a 
Michael–aldol reaction with methacrolein.119 Shibasaki’s second and successfully 
completed approach to garsubellin A used an aldol reaction and an O-allylation to install 
vinyl and allyl groups at the α- and α´-positions of a cyclohexanone, then used a ring-
closing metathesis to form the three-carbon bridge.90  Danishefsky and Nicolaou used 
biomimetic approaches, namely electrophile-mediated cyclizations of a pendant prenyl 
group,91,120,121 Young used an intramolecular [3 + 2] cycloaddition between an allene and 
a pendant nitrile oxide,122 and Kraus and Mehta both used an intramolecular metal-
catalyzed addition of a ketone to a pendant alkene.123-125  Our group have also used an 
α,α´-annulation, with key steps of a lead-mediated alkynylation followed later by an 
aldol reaction (Chapter 3).126  Nicolaou’s first approach was unique because it annulated 
the three-carbon bridge containing the quaternary center (gem-dimethyl group) onto the 
cyclohexanone,120,121 whereas all others annulated the three-carbon bridge containing the 
β-dicarbonyl moiety.   
2.1.  Nicolaou’s Se-mediated electrophilic cyclization approach 
The first efforts toward synthesis of a PPAP were done by Nicolaou. 120,121  The 
model compound 128 chosen by Nicolaou’s group contained the key structural features 
of garsubellin A (26), including the extra ring fused to the bicyclic core (Scheme 2.1) but 
it was a rather long approach with no less than 23 steps.  The lactone ring of 128 was 
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formed by a Baeyer–Villiger reaction of cyclobutanone 129, which was derived from 130 
via a [2 + 2] cycloaddition.  The C(7)–C(12) bond of 130 was derived from C(7) selenide 
131 via radical addition to an alkenyl sulfone, and the C(1)–C(6) bond of 131 was 
constructed by electrophilic cyclization of the prenylated β-keto ester 132.   
Scheme 2.1:  Nicolaou’s retrosynthesis of garsubellin A.   
 
O
O
O
OH
O3
5
18 SO2Ph
O
O
O
18 OH O
O
MeO
13
5
Garsubellin A (16)
128
SO2Ph
O
2
18 OH O
O
RO
O
129
3
CO2Me
18
OH
O
SO2Ph
O
130
CO2Me
18
O
O
O
SePh
7
7
7
7
131
12
12
12
O
CO2Me
OAc
H
1
132  
 
The synthesis of 128 began with C-alkylation of 1,3-diketone 133 and 
stereoselective reduction to give diol 134 (Scheme 2.2).  Hydrolysis of the ester of 134, 
lactonization with DCC and 4-DMAP, and oxidation of the remaining alcohol provided 
keto lactone 135.  Deprotonation of 135, treatment with methyl cyanoformate, and 
acetylation gave enol acetate 132.  The key step of the synthesis, the selenium-mediated 
cyclization, occurred upon addition of SnCl4 to a mixture of 132 and N-
(phenylseleno)phthalimide at –23 °C to give bicyclo[3.3.1nonane 131 in 95% yield.  The 
PhSe group in 131 was placed exclusively in the thermodynamically favored exo 
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orientation.  Stereoselective reduction of the ketone of 131 provided a secondary alcohol, 
which was further converted to vinylogous sulfonate 136 upon addition of trans-1,2-
bis(phenylsulfonyl)ethylene.  Treatment of 136 with n-Bu3SnH and AIBN formed the 
C(7)–C(12) bond, and global reduction gave triol 137. 
Scheme 2.2:  Nicolaou’s approach to garsubellin A, part 1.   
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The least hindered hydroxyl group of 137 was protected, and the remaining 
primary alcohol was oxidized to the aldehyde (Scheme 2.3).  Addition of i-PrMgBr 
resulted only in reduction of the aldehyde, but isopropenylmagnesium bromide not only 
added stereoselectively to the aldehyde, but it also promoted β-elimination of the β-
alkoxy sulfone side chain to give triol 138.  Conditions to reduce both C=C π bonds of 
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138 could not be identified, so the isopropenyl group was reduced with H2 and PtO2, and 
addition of triphosgene and pyridine gave the cyclic carbonate 139.  Hydrogenation of 
139 was then followed by oxidation of the remaining hydroxyl group to the ketone.  
Conversion of the ketone to the enone 140 proved to be challenging, and it could be 
accomplished only by addition of SeO2 in AcOH at 110 °C.  The light-promoted 
cycloaddition of dimethoxyethylene to 140 occurred regio- and stereoselectively from the 
exo-face of the enone.  The dimethoxyketal thus formed was converted to cyclobutanone 
141 upon hydrolysis with H2SO4.  The TBDPS group of 141 was removed, and the C(4) 
ketone was protected as the cyclic methyl acetal.  Treatment with excess m-CPBA then 
promoted a regioselective Baeyer–Villiger reaction of the cyclobutanone to give the 
desired model lactone 128 in good yield.   
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Scheme 2.3:  Nicolaou’s approach to garsubellin A, part 2.   
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2.2.  Danishefsky’s I-mediated electrophilic cyclization approach 
Very recently, Danishefsky has described a total synthesis of garsubellin A that 
uses an electrophilic attack of a cyclohexanone on a prenyl group, reminiscent of that 
described by Nicolaou.91  The beauty of this synthesis is not only that is relatively short 
but also that in the key steps it uses some very interesting and creative iodine-based 
reactions. The main drawback of Danishefsky’s synthesis is that the introduction of the 
C(1) acyl group proceeds in fairly poor and variable yield and that it is a racemic 
synthesis. Future work is needed to extend this methodology to the synthesis of other 
PPAPs such as hyperforin.   
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In Danishefsky’s retrosynthetic analysis (Scheme 2.4), the C(1) acyl group of 16 
would be introduced by deprotonation of 142 and addition of isobutyraldehyde.  The C(7) 
prenyl group of 142 would be introduced by free-radical allylation of the iodide 143.  
Removal of the C(3) allyl group of 143 and disconnection of the C(1)–C(8) bond by an 
iodocyclization reaction then led back to bicyclic 144, which would be produced by 
dihydroxylation and alkylative dearomaticization of the phloroglucinol derivative 145.   
Scheme 2.4:  Danishefsky’s retrosynthesis of garsubellin A.   
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The Danishefsky synthesis of 12 began by deprotonation of 146 and addition of 
prenyl bromide to give 145 (Scheme 2.5).  Nonasymmetric Sharpless dihydroxylation of 
145 was followed by acetonide formation and removal of the TIPS group to give 147.  
Compound 147 was treated with allyl methyl carbonate in the presence of Pd(OAc)2, 
Ph3P, and Ti(O-i-Pr)4, providing key dearomatized intermediate 148, either by direct C-
allylation or by O-allylation followed by a Pd-catalyzed Claisen rearrangement.  Acidic 
hydrolysis of 148 removed the acetonide group and promoted conjugate addition of the 
nascent secondary alcohol to the ring to give a bicyclic acetal, forming the key O-C(4) 
bond; it followed the elimination of MeOH from the acetal and the hydrolysis of the other 
methyl enol ether eventually provided 144 as a single diastereomer.   
The allyl group of 144 was subject to to convert it into a prenyl group, and, in a 
step reminiscent of Nicolaou’s original approach, iodocyclization then provided the 
tricyclic diiodide 149.  Compound 149 was iodinated once again, at C(3), and halogen–
metal exchange followed by treatment with allyl bromide not only introduced the allyl 
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group at C(3), but also promoted Wurtz-like coupling of C(1) and C(7).  Fortunately, this 
cyclopropanation step was easily reversed by addition of TMSI, affording 143.   
Scheme 2.5:  Danishefsky’s synthesis of garsubellin A.   
 
O
OO
HO O
i-Pr
1
16
O
OO
HO
7
142
O
I
OO
HO
3
143
1
8
OO
HO
149
O
OTIPSMeO
OMe146
nBuLi
Br
OTIPSMeO
OMe145
OHMeO
OMe147
O
O
1. K2OsO4   2H2O,.
2. TsOH, 2,2-dimethoxypropane
3. TBAF, 70% (4 steps)
OMeO
OMe 148
O
O
Pd(OAc)2, PPh3,
allyl methyl carbonate,
 Ti(i-PrO)4, 62%
HClO4
H2O/dioxane
71%
I
I
4
7
1
3
2. i-PrMgCl
3. allyl bromide
    Li2CuCl4, 67%
4. TMSI then 1N HCl
     98%
1. allyltributyltin-C6H6
    AIBN, 82%
2. Grubb's cat., 
  2-methyl-2-butene, 73%
1. LDA, TMSCl then I2, 25%
2. i-PrMgCl, then isobutyraldehyde, 72%
3. DMP
4. Et3N(HF)3, 88% (2 steps)
OO
HO
4
144
5
O
1. Grubbs cat., 68%
2. KI, I2, KHCO3
   85%
1. I2, CAN, 77%
 
Iodide 143 was subject to free-radical allylation with allyltributyltin, installing the 
allyl group selectively in the sterically less hindered exo position, and another Grubbs 
cross-metathesis with 2-methyl-2-butene provided the diprenylated compound 142.  
Finally, formation of the bridgehead silyl enol ether of 142, iodination to give the 
bridgehead iodide, halogen–metal exchange and addition of isobutyraldehyde, and 
oxidation of the alcohol gave 16.   
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2.3.  Shibasaki’s addition–elimination–aldol approach 
Shibasaki’s group chose as their model compound 7-deprenylgarsubellin A, 150 
(Scheme 2.6), which has all the features of garsubellin A (16) except the prenyl group 
attached to C(7).116  Their plan was to introduce the C(3) prenyl group in the last step via 
a Stille coupling reaction between tributylprenyltin and the iodide prepared from β-
alkoxy lactone 151.  The C(4)–O bond of 151 would be constructed via an intramolecular 
Wacker-type reaction of enone 152.  The bicyclo[3.3.1]nonane core of enone 152 was to 
be constructed by a stereospecific addition–elimination reaction between 1,3-diketone 
153 and α,β-unsaturated ester 154 followed by a Dieckmann reaction.  This key step 
failed to work as planned, and considerable synthetic effort would be required to arrive at 
152.   
Scheme 2.6:  Shibasaki’s retrosynthesis of garsubellin A.   
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The synthesis began with conjugate addition of MeMgBr to α,β-unsaturated 
ketone 155 followed by trapping of the enolate with isobutyraldehyde to give 156 as a 
single stereoisomer (Scheme 2.7).116  The OH group of 156 was protected, and the 
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product was alkylated with ethyl bromoacetate to give 157 as a single trans isomer.  
Partial reduction of 157 with DIBAL and cyanosilylation of the aldehyde afforded 158 as 
an inconsequential 1.3:1 mixture of diastereomers.  Addition of a higher order 
methylcuprate reagent to 158 gave a methyl ketone, which was further subjected to 
methylation and protection to give the acetonide 159.  Removal of the TBS group with 
BF3·Et2O and oxidation of the resulting secondary alcohol with Dess-Martin periodinane 
gave key intermediate 153 as an inconsequential 1.3:1 mixture of diastereomers.  
Unfortunately, the addition–elimination reaction between 1,3-diketone 153 and cis-β-
chloroacrylate 154 failed to proceed as desired.  The authors expected that addition–
elimination would occur with retention of configuration about the electrophilic π bond, 
and a Dieckmann condensation would then give 152 (protected as the acetonide).  
Instead, the major product was the trans acrylate 160.  The authors found that 160 could 
be converted into 161 in the presence of p-nitrophenol and base.  Extensive optimization 
finally uncovered conditions under which 153 could be directly converted to 161 in good 
yield.  Unfortunately again, the major diastereomer produced under these conditions was 
the undesired 161a.   
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Scheme 2.7:  Shibasaki’s approach to garsubellin A, part 1.   
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Later, the Shibasaki group found that the carbonate 162 gave a much less 
diastereoselective addition–elimination reaction than the acetonide 153 did, affording 
larger quantities of the desired epimer 163b (Scheme 2.8).115   
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Scheme 2.8:  Shibasaki’s approach to garsubellin A, part 2.   
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Conjugate addition of an aminosilylcuprate to α,β-unsaturated lactone 163b and 
immediate Tamao–Fleming oxidation with mCPBA afforded a β-hydroxy lactone, which 
was protected with a TES group to give 164 in modest yield over the three steps (Scheme 
2.9).115  Preparing the substrate for an aldol condensation, the lactone ring of 164 was 
opened with Me2AlSEt to give the corresponding thioester, Fukuyama reduction of the 
thioester gave an aldehyde, and the aldehyde underwent an aldol reaction upon treatment 
with Al2O3, with Dess-Martin periodinane treatment affording triketone 165.  From this 
point, the sequence of reactions went as planned in the retrosynthetic analysis.  Thus, 165 
was converted to enone 166 by DBU-promoted β-elimination of TESOH.  Deprotection 
of the carbonate of 166 with LiOH was followed by Wacker oxidation to afford the β-
alkoxy enone 151.  Treatment of 151 with I2 and CAN afforded the vinyl iodide, and 
Stille coupling with tributylprenyltin catalyzed by PdCl2(dppf) introduced the prenyl 
group on C(3) and completed the synthesis of 150.  The acetonide 161a with the 
unnatural C(18) configuration was also carried on to the C(18) epimer of 150 via a 
similar sequence of reactions.116   
Shibasaki later found that the aldol reaction leading from 164 to 165 failed when 
there was a prenyl group at C(7)90  and the group abandoned this approach to garsubellin 
A. They later reported the total synthesis of garsubellin A in which a very different 
approach was used. 
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Scheme 2.9:  Shibasaki’s approach to garsubellin A, part 3.   
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2.4.  Stoltz’s Claisen–Dieckmann approach 
Stoltz’s approach to the PPAPs (Scheme 2.10) had the advantage of producing a 
diprenylated bicyclic core in just 10 steps,117 but it also had the disadvantage of not being 
suitable for substrates with substituents at the α-position. The retrosynthesis of model 
compound 167 began with disconnection of the C(3) prenyl group to give 168. The 
bicyclic core would then be introduced by a condensation reaction between silyl enol 
ether 169 and malonyl dichloride, similar to the reaction reported by Effenberg in 
1984,127 in which 1-methoxy-1-cyclohexene reacted with malonyl dichloride to give a 
bicyclo[3.3.1]nonane-2,4,9-trione.   
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Scheme 2.10:  Stoltz’s retrosynthesis of PPAPs.   
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The synthesis of 167 began with α-prenylation of β-alkoxy enone 170 (Scheme 
2.11).  Addition of MeLi and acidic workup then gave α,β-unsaturated ketone 171.  
Conjugate addition of dimethyl cuprate to 171 and subsequent addition of TBSCl 
provided the silyl enol ether 169.  Under optimal conditions, compound 169 underwent 
α,α´-annulation with malonyl dichloride to give the bicyclo[3.3.1]nonane-2,4,9-trione 
168 as a single diastereomer in 36% yield.  Unreacted enol ether was recovered in 59% 
yield as the keto form of 169, which could be used again in the reaction sequence.  
Although the cyclization step proceeded only in modest yield, the previous steps were 
relatively easy to pursue and proceeded in excellent yields.   
The introduction of the C(3) prenyl group into 168 began by treatment with allyl 
alcohol under acidic conditions under a Dean–Stark trap.  Thermal Claisen rearrangement 
followed by methylation with CH2N2 afforded the C-allylated β-alkoxy enone 172.  
Finally, olefin cross-metathesis with 2-methyl-2-butene catalyzed by Grubbs’ second-
generation catalyst and subsequent saponification of the methyl ether with aqueous 
NaOH gave the final target model compound 167.   
 59
   
Scheme 2.11:  Stoltz’s approach to garsubellin A.   
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Stoltz tried to extend this methodology to analogs of 167 which would contain 
quaternary bridgehead C atoms, but most attempts failed, suggesting that the presence of 
substituents at the α-positions of the masked ketone affected the reactivity of the system.  
After prolonged experimentation, the group eventually found  a way in which the methyl 
enol ether of 2,6-dimethylcyclohexanone would react with malonyl dichloride to give a 
bicyclo[3.3.1]nonane-2,4,9-trione but the product was obtained only in 25% yield, 
proving indeed that substituted enol ethers are not good substrates for the Claisen–
Dieckmann approach.   
2.5.  Nicolaou’s Michael–aldol approach 
In a recent publication very different from his previous approach, Nicolaou 
showed that 2-acylcyclohexanone 173 (and 2-acylcycloalkanones of other ring sizes) 
underwent a TfOH-catalyzed tandem Michael–aldol reaction with methacrolein   
(Scheme 2.12).119  Oxidation of the aldol product with Dess–Martin periodinane then 
afforded bicyclic triketone 174, and desaturation of 174 to give 175 was easily 
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accomplished by selenation and oxidation.  This strategy had the advantage of forming 
the two quaternary centers in just one step in relatively good yield from a simple cyclic 
ketone and aldehyde. The authors did not report whether the Michael reaction would 
proceed as readily when there was a quaternary center at C(3) of 173.  Conversion of the 
enone functionality of 175 to a β-diketone remained to be accomplished.   
Scheme 2.12:  Nicolaou’s Michael–aldol approach to PPAPs.   
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2.6.  Shibasaki’s ring-closing metathesis approach 
Shibasaki’s group has very recently published a total synthesis of racemic 
garsubellin A.90  Disconnection of the C(3) prenyl group of 16 gave 176, whose O–C(4) 
bond was expected to be formed by an intramolecular Wacker oxidation, as precedented 
in the group’s earlier studies,115 leading back to enone 177 (Scheme 2.13).  Because their 
previous intramolecular aldol route failed when a C(7) prenyl group was present, the 
authors decided to introduce the enone bridge of 177 by ring-closing metathesis of the 
very congested α-vinyl α´-allyl cyclohexanone 178.  The key C(1) and C(5) quaternary 
centers of 178 were introduced into simpler ketone 179 by an aldol reaction and 
dehydration (vinyl group) and by an O-allylation and Claisen rearrangement (allyl 
group).  The ketone 179 was elaborated from simple enone 171, an intermediate found 
also in Stoltz’s studies (Scheme 15).117   
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Scheme 2.13.  Shibasaki’s ring-closing metathesis approach to garsubellin A.   
O
OO
HO O
i-Pr
7
16
O
O
I
O
HO O
i-Pr
4
176
3
O
OOH
HO O
i-Pr
5
177
HO
O
O
i-Pr
MOMO
O
O
O
1
178
O
H OTIPS
i-Pr
MOMO 179
O
171
 
 
Copper-catalyzed conjugate addition of MeMgBr to 171, trapping of the enolate 
with isobutyraldehyde, and protection of the resulting OH group with a TIPS group 
provided ketone 180 (Scheme 2.14).  The prenyl group of 180 was hydrated and 
protected with a MOM group, and the ketone was then alkylated at the less hindered α-
position, C(5), with prenyl bromide to give ketone 179.  Another deprotonation of 179, 
again at C(5), was followed by another aldol reaction, this time with acetaldehyde; this 
reaction proceeded in surprisingly good yield, despite the tendency of sterically crowded 
aldols to fragment by a retro-aldol reaction.  Dehydration of the aldol with Martin 
sulfurane then gave the α-vinyl ketone 181.  The prenyl group was then subject to 
Sharpless dihydroxylation with AD-mix-α, which provided the diol with zero 
diastereoselectivity.  Formation of the carbonate and separation of the diastereomers gave 
182.  The TIPS group of 182 was removed, the aldol was oxidized to the β-diketone, the 
ring O atom was allylated with allyl iodide, and a Claisen rearrangement on the face 
opposite the C(7) prenyl group provided fully quaternized diketone 178 with very high 
diastereoselectivity.   
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Scheme 2.14:  Shibasaki’s synthesis of garsubellin A, part 1.   
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Ring-closing metathesis of 178 proceeded smoothly with the Hoveyda–Grubbs 
catalyst, and the resulting alkene was oxidized in the allylic position with (PhSe)2 and 
PhIO2 (scheme 2.15). MOM protecting group was then removed to give 183.  After 
deprotection of the diol, the alcohol and enone moieties were condensed oxidatively in 
the intramolecular Wacker oxidation that worked so well in Shibasaki’s earlier work, and 
C(3) iodination and acid-catalyzed dehydration of the tertiary alcohol gave 176.  Finally, 
Stille coupling of 176 with tributylprenyl tin afforded the target, 16, in a total of 21 steps 
from 171.   
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Scheme 2.15:  Shibasaki’s synthesis of garsubellin A, part 2.   
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Shibasaki also showed that alkylation of the Li enolate of 2-cyclohexenone with 
prenyl bromide in the presence of catalytic amounts of chiral tetraamine 184 (Figure 2.1), 
whose synthesis has not been published yet, gave 6-prenyl-2-cyclohexenone with 95% ee 
in 65% yield.  This compound could then be converted to 171 by addition of MeLi and 
PCC oxidation.   
N
N
H
Me
N
NMe2
184
 
 
Figure 2.1:  Chiral amine catalyst for asymmetric prenylation of 2-cyclohexenone.   
 
Shibasaki’s synthesis of garsubellin A is an important contribution to the 
synthesis of PPAPs, but it has some deficiencies. The dihydroxylation of 181 proceeded 
with no diastereoselectivity.  Also, the oxidation of the C(2–4) enone of 183 to the β-
alkoxy enone of 176 in the intramolecular Wacker oxidation relied on an internal OH 
group that attacked the enone–Pd complex in intramolecular fashion.  Although this 
method is perfectly suitable for PPAPs with a tetrahydrofuran ring fused to the C(4,5) 
bond, such as garsubellin A, it is much less so for PPAPs (such as hyperforin, 1) that lack 
this feature.   
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2.7.  Kraus’s addition–elimination–addition approach  
Kraus found that β-keto ester 185 and diacetoxy vinyl sulfone 186 underwent a 
base-promoted addition–elimination reaction to give 187 (Scheme 2.16).118  
Transesterification of the acetate of 187 to the pivalate was followed by another base-
promoted addition reaction to give bicyclic keto ester 188, and acetylation of 188 
followed by treatment with sodium amalgam gave alkene 189.  This method had the 
virtue of producing quaternary centers at both bridgehead C atoms of 189, but no reports 
have been made so far regarding the functionalization of the alkene. 
Scheme 2.16:  Kraus’s addition–elimination–addition approach to PPAPs.   
H3C CO2Me
O
+
SO2Ph
OAc
OAc
NaH
71%
H3C
CO2Me
O
SO2Ph
OAc
t-BuOK
O
CO2MeH3C
SO2Ph
HO
20%
1. (AcO)2O, DMAP
    95%
2. Na/Hg
    MeOH, 57%
O
CO2MeH3C
185 186 187
188 189  
 
 65
   
2.8.  Kraus’s Mn-mediated oxidative free-radical cyclization approach 
In an earlier approach to the synthesis of PPAPs, Kraus utilized a Mn(III)-based 
oxidative free-radical cyclization of unsaturated β-keto ester 190 to give bicyclic keto 
ester 191 (Scheme 2.17).123,124  Treatment of 191 with 3.5 equivalents of NBS followed 
by hydrolysis afforded β-bromo enone 192 as a single regioisomer.  Substitution of the 
bromide with an allyloxy group followed by a Claisen rearrangement then gave 193.  The 
main drawback of this approach was the lack of a substituent on C(5) and it was not clear 
whether the Mn(III)-based oxidative free-radical cyclization would work on the more 
complex substrates necessary to build the PPAPs’ core. 
Scheme 2.17:  Kraus’s oxidative free-radical cyclization approach to PPAPs.   
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2.9.  Mehta’s Pd-mediated oxidative cyclization approach 
The first enantioselective approach to a PPAP was achieved by Mehta, who used 
(–)-α-pinene as the starting material in this rather lengthy approach.125  Compound 194 
(Scheme 2.18) was chosen as a model for nemorosone (5).  As one can see, the model 
compound 194 lacked a lot of functionality, and no work has been reported so far to 
prove that the methodology can be applied to a more functionalized system. 
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Scheme 2.18:  Mehta’s retrosynthesis of PPAPs.   
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In a strategy similar to that of Kraus, alkene 194 was disconnected at the C(1)–
C(2) bond to give the monocyclic, diprenylated 2-acylcyclohexanone 195.  Removal of 
the α-allyl and -acyl groups from 195 gave the diprenyl cyclohexanone 196, which would 
be prepared by elaboration of ester 197.  Ester 197 would be prepared from cyclohexenol 
198, which, in turn, would be prepared from (–)-α-pinene.   
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Scheme 2.19  Mehta’s approach to PPAPs.   
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α-Pinene was stereoselectively epoxidized, and the product fragmented upon 
addition of ZnBr2 to give campholenic aldehyde 199 (Scheme 2.19).
128,129  OsO4-
catalyzed dihydroxylation of 199 and Wittig reaction of the aldehyde group with 
Ph3P=CMe2 gave the prenylated diol 200.  Oxidative cleavage of 200 with sodium 
periodate gave a keto aldehyde, which underwent intramolecular aldol cyclization to give 
an enone.  A Luche reduction of the ketone occurred from the face opposite the prenyl 
group, producing allylic alcohol 198 with high selectivity.  Compound 198 then 
underwent a stereospecific orthoester Claisen rearrangement to provide ester 197.  
Hydrolysis of 197, iodolactonization, and reductive deiodination with Bu3SnH gave 
lactone 201.  Reduction of the lactone to the lactol and a second Wittig reaction 
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introduced the second prenyl group in moderate yield, and oxidation of the alcohol 
provided cyclohexanone 196.  The thermodynamic enolate of ketone 196 was formed 
with NaH, and alkylation with allyl bromide occurred exclusively from the kinetically 
favored axial direction to give triene 195 stereoselectively.  In the key step, ketone 195 
was converted to its silyl enol ether, and oxidative cyclization promoted by Pd(OAc)2 
gave the bicyclic compound 194 in modest yield.   
2.10.  Young’s intramolecular allene–nitrile oxide cycloaddition approach 
Young described an ingenious approach to the PPAPs that was completely 
different from all others to date (Scheme 2.20).122  His method had the advantage that it 
was quite short and did not rely on carbonyl condensation reactions to form the key 
bonds, but it had the drawback of lacking of a substituent at C(5) of the model compound, 
as in the case of Stoltz’s and Mehta’s approaches. 
Young proposed that the nonenolizable β,β´-triketone group of model compound 
202 be derived from alkylidene isoxazole 203. The latter could in turn be prepared from 
204 by an intramolecular nitrile oxide–allene cycloaddition.  The allenic ketone 204 
would be prepared from alkylidene cyclohexanone 205.   
Scheme 2.20:  Young’s retrosynthesis of PPAPs.   
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Addition of propynylmagnesium bromide to 205 and ozonolysis of the double 
bond gave α-hydroxyketone 206 (Scheme 2.21).  Reduction of 206 with LiAlH4 gave a 
1,2-diol (as a mixture of diastereomers), which was further converted to the carbonate 
after treatment with carbonyl diimidazole.  Conjugate addition of dimethyl cuprate to this 
propargyl carbonate then provided allenic alcohol 207.  The alcohol 207 was oxidized to 
the ketone and converted to the silyl enol ether, and a TiCl4-promoted aldol condensation 
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between this compound and the dimethyl acetal of 3-nitropropanal afforded nitro 
compound 204 as a mixture of diastereomers.  The key step of the synthesis, the 
intramolecular nitrile oxide–allene cycloaddition, occurred after addition of phenyl 
isocyanate and Et3N to 204 to give bicyclic adduct 203 in 40% yield and as a single 
diastereomer.  Reductive cleavage of the isoxazoline ring with methanolic Raney nickel 
afforded primary enamine 208, which has most of the features of the PPAPs.   
Scheme 2.21:  Young’s approach to PPAPs.   
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2.11. Grossman’s alkynylation–aldol approach 
Our synthetic approach to the bicycle[3.3.1]nonane skeleton involves a novel 
three-carbon α,α′-annulation of a sterically hindered cyclic β-keto ester with 3,3-
diethoxypropyne. More details of this approach are presented in the next chapter. 
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Chapter 3. Our approach to PPAPs 
3.1. Attempted biomimetic route to type B PPAPs 
 We started this project by exploring a biomimetic route to 7-epi-clusianone, a 
type B PPAP. The retrosynthesis is described in Scheme 3.1, and it starts with the 
masking of the prenyl groups with allyl groups; we plan to introduce the prenyl groups 
through a Ru-catalyzed cross-metathesis of 209 with 2-methyl-2-butene.117,123,124. The 
allyl group on C(7) is introduced by a free-radical allylation of selenium derivative 210 
which, in turn, is formed through a Se-promoted cyclization of 211.120,121 The prenyl 
group of 211 is introduced by adding prenyl bromide in liquid ammonia to 212. The 
precursor for 212 is benzoylphloroglucinol 213 which is readily available from 
phloroglucinol 214.  
 Unfortunately, poor yields have thwarted this route. Moreover, while working on 
this approach, we have obtained good results with the non-biomimetic route, and we 
continued with pursuing the synthesis of type A PPAPs (see next section). 
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Scheme 3.1: Retrosynthetic analysis for 7-epi-clusianone. 
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3.2. Retrosynthetic analysis for nemorosone 
We focused our attention on nemorosone (5)126 because it has a fairly simple 
structure relative to other A PPAPs and it also shows antibacterial, antioxidant and 
cytotoxic activity. The retrosynthetic analysis (Scheme 3.2) started with masking the 
sensitive prenyl groups as more robust allyl groups until the end of the synthesis, when 
they could be installed by Ru-catalyzed cross-metathesis of 215 with 2-methyl-2-
butene.117,123,124 The allyl group on C(3) would be installed by alkylation of the β-
diketone group, whereas the C(4)−C(5) bond would be formed through an intramolecular 
aldol reaction of 216. The key step of the retroanalysis was the construction of the 
C(1)−C(2) bond which would lead to formation of a product possessing two adjacent 
quaternary C atoms. Previous work in Dr. Grossman’ lab regarding the synthesis of 
sterically congested compounds by the use of CN groups130 led us to speculate that a 1-
alkynyl group could be added to C(1) of 218 without much steric impedance from the 
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adjacent gem-dimethyl group. In fact, the Hashimoto and Moloney groups developed 
Pb(OAc)4-mediated alkynylations of β-keto esters in the late 1980s131,132 although they 
did not investigate substrates as hindered as 218. Having known this, we decided that the 
next disconnection to be C(1)−C(2) in 217, bond that would be constructed by 
alkynylation of 218 with commercially available 3,3-diethoxypropyne.  
Scheme 3.2: Retrosynthetic analysis for nemorosone. 
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3.3. Building the substrate for alkynylation 
Our investigation started with a model study. The model compound is depicted in 
Figure 3.1. As one can see, its structure is very similar with that of nemorosone; only the 
prenyl group on C(7) is missing.  
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O
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1
MeOOC
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model compound 
Figure 3.1: Nemorosone and model compound structures 
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 Our forward synthesis started with addition of allyl bromide to the commercially 
available methyl acetoacetate 219 (Scheme 3.3). Allylated ester 220 was easily made on a 
large scale in 81% yield, after the dianion of 220 was formed by adding NaH and BuLi in 
this order. 
Scheme 3.3: Addition of allyl bromide to 219. 
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Addition of prenyl bromide (Scheme 3.4) to the dianion of methyl 3-oxo-6-
heptenoate 220 gave diene 221 in low yield (23-35%). However, when DMPU (N,N′-
dimethylpropyleneurea) was added, a better yield was obtained (67%).  
Scheme 3.4: Addition of prenyl bromide to the dianion of 3-oxo-6-heptenoate 220. 
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Cyclization of 221 proceeded through an intramolecular cationic reaction. 
Addition of 1.5 equivalents of SnCl4133,134 to 221 in dichloromethane provided 222 in 
84% yield (Scheme 3.5). Thus, the required gem-dimethyl group was introduced in the 
first ring of the bicyclo[3.3.1]nonane core. 
Scheme 3.5: Cyclization of 221. 
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Another attempted route to compound 222 was the introduction of the prenyl 
group first, cyclization to compound 223, and only at the last step addition of an allyl 
group to C(5) (Scheme 3.6). This route, though, did not provide a very good yield (31% 
over three steps). 
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Scheme 3.6: Another route to 222. 
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3.4. Alkynylation reaction 
The next step was a very challenging one because we had to form a quaternary 
center adjacent to the gem-dimethyl group. We tried first Hashimoto’s procedure131 using 
1-hexyne 224 and β-ketoester 225 (Scheme 3.7). Alkyne-ester derivative 226 was formed 
in 53% yield.   
Scheme 3.7: Alkynylation of 225. 
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224
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CO2Me
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We were pleased with the result, and we next applied this procedure to 3,3-
diethoxypropyne (228) and substrate 222, but the desired alkynyl derivative of 222 was 
obtained in only 7% yield. The only significant products were the starting material (31%) 
and a 1,3-diyne compound (227, 13%) (Figure 3.2).  
EtO
EtO
OEt
OEt
227  
Figure 3.2: The 1,3-diyne by-product 
However, when the tributylstannyl alkyne 229132 was used in the reaction,  and 
the order of addition of  222 and lead tetracetate was reversed, the alkyne derivative 230 
was obtained in 53% yield (Scheme 3.8). The stereochemistry of 230 is assigned as 
shown because H(5) is deshielded from H(5) in 222 due to the close proximity of the 
triple bond; the H(5) and alkynyl group are coaxial. 
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Scheme 3.8: Alkynylation with tributylstannane alkyne 229. 
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The proposed mechanism of this reaction is outlined in Scheme 3.9. The negative 
carbon of the enolate 231 attacks the alkynyllead intermediate 232, formed from 
tributylstannyl alkyne 229 and Pb(OAc)4, and a new lead derivative 233 is formed in 
which the lead is in the axial position. Compound 233 undergoes a reductive elimination 
with formation of the desired alkyne 230. Konopelski135 has shown that various 
substituted methyl 2-oxo-1-cyclohexanecarboxylates undergo the lead-mediated α-
arylation reaction with formation of a 2-(alkynyllead)cyclohexanone as the intermediate, 
which further goes through a reductive elimination to the product with the aryl group in 
axial position. 
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Scheme 3.9: The proposed mechanism for alkynylation reaction of enolate 231.  
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We mentioned earlier that formation of the desired alkyne product vs the 1,3-
diyne by-product depends on the nature of the alkynylmetal intermediate. We explain this 
behavior as follows: the alkynyllithium derivative (234, M = Li) is more reactive than its 
Sn homologue (234, M = Sn), so the formation of 238 and the conversions of 235 to 236, 
236 to 238, and  237 to 240 proceed faster and the formation of 240 is favored (Scheme 
3.10). When a tributylstannyl alkyne is present, all the above-mentioned steps are slower 
relative to the 236→239 transformation, so the desired alkyne product is formed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 77
   
Scheme 3.10: Formation of the alkyne product vs the 1,3-diyne by-product.  
Pb
OAc
OAc
OAc
AcO
M R
Pb
OAc
OAc
AcO
CO2Me
O-
CO2Me
O
R
231
O
CO2Me
Pb
AcO OAc
R
M R
Pb
OAc
AcO R
R
O
CO2Me
Pb
OAc
R
R
M R 231
R
235
234
236
237
238239 240
R R
 
3.5. Formation of the bicyclo[3.3.1]nonane skeleton 
At this point, the syn reduction of the triple C≡C bond to a cis double bond would 
give the right stereochemistry necessary for the planned aldol reaction. Although 
hydrogenation of model compound 226 with Lindlar catalyst at 3 atm worked beautifully, 
the cis-adduct being formed in 87% yield, when we tried hydrogenation of 230, the 
reduction of the allylic double bond occured faster than the alkyne triple bond. We 
believed that this behaviour was due to a combination of steric and electronic effects. The 
acetal group hindered the triple bond so the reagents could not reach it well. The acetal 
group is also an electron withdrawing group and makes the triple bond less reactive. 
Subsequently, we have converted acetal 230 to aldehyde 241 (Scheme 3.11) in neat 
HCO2H in 71% yield.  
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Scheme 3.11: Conversion of acetal 230 to aldehyde 241. 
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Unfortunately, all attempts at the catalytic hydrogenation of 241 failed, even at 
very high pressures (ca. 1000 psi). We have tried numerous conditions for this reaction, 
changing the reagent, the solvent, and the pressure, but starting material alone, starting 
material together with hydrogenated C=C bond, trans product, or even hydrogenated 
carbonyl were obtained (Table 3.1). 
Table 3.1: Attempts for hydrogenation of 241  
No. reagent catalyst solvent product 
1 H2 Lindlar MeOH, r.t., 1 atm 241 
2 H2 Lindlar EtOAc, quinoline 
3 H2 Lindlar MeOH or THF 
241 and/or cis  C=C and 
saturated C≡C bond 
4 HCOOH Pd/C Et3N Hydrogenated  
carbonyl group (aldehyde) 
5 H2 Pd/CaCO3 pyridine trans product 
 
Alternatives to the syn hydrogenation of the C≡C triple bond were sought after 
many attempts to perform catalytic hydrogenation of 230 using various conditions. A 
literature survey revealed very few alternatives to Lindlar-type hydrogenation for the syn 
reduction of alkynes in the presence of unhindered alkene and carbonyl groups. Only one 
precedent stood out: an alkyne was syn hydrosilylated with Et3SiH via its Co2(CO)6 
complex, and terminal alkenes in the substrate were unaffected.136,137 
We obtained the Co2(CO)6 complex of 241 in 87% yield, despite the steric 
encumbrance around the C≡C bond in 241. A 1H NMR spectrum could not be recorded 
for the cobalt complex 242 probably because of the presence of some paramagnetic Co 
by-products. Treatment of the complex 242 with excess Et3SiH in the presence of 
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Me3SiC≡CSiMe3 gave the (E)-α-silyl enal 243 in 94% yield with complete regio- and 
stereoselectivity (Scheme 3.12). The triple bond from bis(trimethylsilyl)acetylene formed 
a red cobalt complex similar to that from 242; in the absence of this coreagent, the 
reaction was very messy, and the desired product 244 could not be purified. 
Scheme 3.12: Syn reduction of alkyne 241. 
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Once the right stereochemistry of the silyl enone was set, we were able to proceed 
to the aldol reaction. Treatment of 244 with aqueous HCl gave two diastereomers, 245a 
and 245b (ca. 1:1 crude dr), in 72% combined yield (Scheme 3.13). The faster moving, 
crystalline diastereomer was initially proposed to be 245a because its 1H NMR spectrum 
showed long-range allylic coupling between H(2) and H(4), whereas that of the slower, 
liquid diastereomer did not. A NOESY spectrum of the latter compound showed a cross-
peak between a resonance attributed to H(4) and one attributed to H(6) or H(7), 
confirming it as 245b (Figure 3.3). The C(4)−H(4) single bond was partially overlapping 
with the π system of the C(2)=C(3) double bond, hence the long-range allylic coupling 
between H(2) and H(4). The assignment of the former compound as 245a was later 
confirmed by X-ray crystallographic analysis (Figure 3.4). 
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Figure 3.3: NOE’s of 4-exo-245 (245b) 
 
 
Scheme 3.13: Formation of the endo and exo aldol adducts.  
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Figure 3.4: X-ray crystal structure of 4-endo-245 (245a) 
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 Desilylation of 245, in the presence of TBAF138,139 led to formation of allylic 
alcohols 246a and 246b in 78% yield (Scheme 3.14). Although the reaction starts with a 
1:1 dr of 245, the outcome of the desilylation is a 4:1 dr (246a:246b) due to 
epimerization. It seems that fluoride anion acts both as a desilylating reagent and a base.  
Scheme 3.14: Desilylation of aldol adduct 245. 
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Although the 246a,b mixture is separable by flash chromatography, we used it as 
a mixture for the following reaction. The oxidation with TPAP/NMO140 led to enone 247 
in 85% yield (Scheme 3.15).  
Scheme 3.15: Oxidation of allylic alcohol 246 to enone 247. 
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3.6. Attempts to form the 2,4,9-triketone system 
The next step would be oxidizing C(2) of 247 to form the 2,4,9-triketone system 
present in PPAPs. We have tried a series of reactions but, unfortunately, all our 
approaches have so far been unfruitful. 
 Our original intention had been to introduce a silyl group through a conjugate 
addition reaction and to convert the C(2)-Si bond into a C(2)-O bond later. To this end, 
we treated 247 with (PhMe2Si)2CuLi in THF (Scheme 3.16), and diketone 248 was 
obtained in 80% yield. (PhMe2Si)2CuLi was formed in situ from PhMe2SiLi and CuI.141 
The assignment of C(2) stereochemistry in 248 was confirmed by X-ray crystallographic 
analysis (Figure 3.5). 
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Scheme 3.16. Silylation of 247.  
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Figure 3.5: X-ray crystal structure of 248  
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Scheme 3.17: Conversion of C(2)-Si bond into C(2)-O bond. 
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Unfortunately, conversion of the C(2)−Si bond into a C(2)−O bond proved to be a 
formidable task. Although there are many precedents in the literature for this conversion, 
none worked for our substrate (Scheme 3.17). When we treated 248 with HBF4·Et2O in 
CH2Cl2 followed by m-CPBA and KF,141 or KF, H2O2 in DMF,142 or BF3·2CH3COOH in 
CH2Cl2 followed by m-CPBA and NEt3,143 only a very messy mixture was obtained. 
When 248 was treated with CF3COOH followed by KF, KHCO3 and H2O2144, the allyl 
and ester group were affected. 
We think that the β-keto ester system affects the reactivity of the C(2)-Si bond. In 
order to prevent this adverse interference, we thought that by reducing the carbonyl 
groups of 248, the reactivity of C(2)-Si bond will resemble more the ones that are in the 
literature. Thus, after reduction of 248 with LiAlH4, we treated the triol thus formed with 
HBF4·Et2O in CH2Cl2 followed KF, H2O2 in DMF under reflux. Unfortunately, 
dehydrosilylation occurred, leading to formation of 250 (Scheme 3.18). The 
configuration at C(9) on 250 was assumed but not proven. 
Scheme 3.18: Dehydrosilylation of 248. 
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We also attempted reduction of C(4) with NaBH4 in MeOH and CH2Cl2 to afford 
alcohol 251 followed by treatment with NaH in DMF and THF145 but a retro-aldol 
reaction occurred instead (Scheme 3.19). 1H and 13C NMR spectra of 252 indicated the 
presence of the H from the aldehyde group as well as the absence of the phenyl group. 
We hoped that the nucleophilic O- atom, formed after deprotonation of OH group with 
NaH, would attack the Si, forming a five-membered ring which could be opened by a 
Tamao-Fleming oxidation reaction. 
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Scheme 3.19: Retro-aldol reaction. 
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 We then, turned our attention to other groups that might be converted into a 
hydroxyl group. Our first choice was a S-based group. However, when PhSH146 in the 
presence of NEt3 was added to enone 247, starting material was recovered. Even in the 
presence of the Lewis acid InBr3,147 the outcome of the reaction was the same. We have 
also tried boration of the α,β-enone with bis(pinacolato)diboron 253. None of the 
conditions used (LiCl/CuCl148 or Bu3P/CuCl149 in DMF at room temperature, Pt(PPh3)4 in 
toluene under reflux150) led us to the desired boron adduct (Scheme 3.20). 
Scheme 3.20: Attempted diboration. 
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Another approach involved conversion of the double bond of the enone into an 
epoxide followed by epoxide opening. Treatment of enone 247 with 30% H2O2 in the 
presence of KHCO3 in MeOH occurred to give the epoxide 254 in 64% yield (Scheme 
3.21). This advanced intermediate clearly possessed all the oxygenated carbons found in 
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the phloroglucinol moiety of nemorosone. Therefore, our next task included two last 
steps: opening of the epoxide and oxidation of the hydroxyl group to the ketone. 
Scheme 3.21: Epoxide formation. 
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 Although there are many examples in the literature in which an epoxide ring is 
opene selectively to form a β-hydroxy ketone, unfortunately for us, nothing that we have 
tried has worked so far (table 3.2). Both the organoselenium-mediated151,152 and the Zn-
mediated153 reductions converted the epoxide 254 back to enone 247. Treatment of the 
epoxide with a titanocene (III) reagent,154 Cp2TiCl2 and Zn in THF in MeOH, resulted in 
formation of enone and Cp2Ti(Cl)−O−Ti(Cl)Cp2; some starting material was also 
recovered. We believe that the enone is formed from intermediate 255 (Scheme 3.22), 
which, instead of reacting with MeOH to become the β-hydroxy ketone, ejects -
OTiCp2Cl; this compound combines with TiCp2Cl to give the titanium-byproduct 256. 
Enone 247 was also formed when we treated epoxide 254 with catalytic amounts of 
tetrakis(triphenylphosphine)palladium(0) and 1,2-bis(diphenylphosphino)ethane. 155 The 
literature reports that a β-diketone is formed in moderate to very good yields under these 
conditions, but all substrates had the epoxyketone present as the only functional group; 
on the other hand, there are many other functional groups in our substrate which could 
affect its reactivity. 
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Table 3.2: Attempts for epoxide ring opening  
No Reagent Conditions Reaction outcome 
1 NaBH4, (PhSe)2 EtOH,  0 ºC→r.t. enone 
2 Zn, AcOH MeOH, reflux enone 
3 Cp2TiCl2, Zn THF, MeOH enone, SM,  
Cp2Ti(Cl)−O−Ti(Cl)Cp2
4 Pd(PPh3)4, dpe toluene, reflux enone, SM 
5 Al(Hg) THF, H2O, EtOH, NaHCO3 messy 
6 Me2CuLi THF or Et2O messy 
7 SmI2 THF, -78 ºC SM 
8 NaTeH EtOH, 0 ºC 
CO2Me
O
HO
257
O
 
9 LiAlH4 THF, reflux 
OH
HO
258
O
OH
9
 
O
HO
259
O
OH
 
 
Scheme 3.22: Tetanocene-mediated reaction. 
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Cl Cl
 
 The same epoxide 254 was found to be resistant toward opening with other 
reducing reagents. Reactions with both aluminum amalgam generated in situ156-158 and 
Me2CuLi159 resulted in messy mixtures, and treatment with SmI2160 had no effect on the 
epoxide. 
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Hydrides are another class of reagents known for opening epoxides. However, our 
substrates proved to be resistant to them, and only ketone reduction occurred. For 
example, NaTeH161 reduced the ketoepoxide to the hydroxyepoxide 257, and LiAlH4 in 
THF under reflux reduced the β-keto ester system with formation of the triol 258 (37% 
yield) and diol 259 (51% yield). The configuration at C(9) on 258 was assumed but not 
proven. 
As discussed so far, all the attempts to form C(2)−O bond (without a C(3) bond) 
failed no matter what approach we tried. The studies on the development of palladium-
catalyzed methods for the oxidative functionalization of sp2-hybridized carbon162-164 
captured our attention. We planned to introduce the oxygen atom intramolecularly by 
activation of the C(2)-H bond of the enone. In order to do this, we first treated the ester 
247 with LiAlH4 to give triol 260 (Scheme 3.23). The configuration at C(9) on 260 was 
assumed but not proven. The crude mixture of triol 260 was further oxidized to acid 261 
using Jones’ reagent. Acid 261 was converted in the next step to acyl chloride 262 which 
upon treatment with pyrazole resulted in the desired acyl pyrazole derivative 263 together 
with some saturated diketone 264 (1.3:1 molar ratio in 50% yield after four steps. 
Compound 264 was obtained probably because part of enone 247 underwent conjugate 
reduction when it was treated with LiAlH4. 
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Scheme 3.23: Formation of the acyl pyrazole derivative 263. 
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 With compound 263 in hand, we proceeded further to regioselective C(2)−H bond 
oxidation. To our surprise, an intermolecular oxidative functionalization of the allyl 
group occurred (Scheme 3.24); upon treatment with iodobenzene diacetate and a catalytic 
amount of Pd(OAc)2, we obtained compound 265 in about 35% yield (some phenyl 
containing by-product was also collected) together with some starting material. 
Scheme 3.24: Attempted oxidation of 263. 
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 We decided first to reduce the enone to an allylic alcohol and then to perform the 
oxidation of C(2) in the hope that a less electron-deficient double bond might be more 
prone to undergo the C(2)−H activation reaction. Enone 263 proved to be resistant to the 
Luche reagent (NaBH4 and CeCl3), and the desired alcohol 266 was obtained in only 30% 
yield, the rest being recovered starting material (Scheme 3.25). We proceeded further to 
the planned oxidation but, unfortunately the allylic alcohol was oxidized back to the 
enone. 
 91
   
Scheme 3.25: Luche reduction. 
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 There are other functional groups that might deliver the oxygen atom to C(2). We 
have oxidized alcohol 260 to diketo aldehyde 267, which in turn will be converted to an 
oxime (Scheme 3.26). We hope that by heating the oxime with catalytic Pd(OAc)2 and 
PhI(OAc)2, we will activate the C−H bond and form the C(2) acetate derivative. The 
palladacycle intermediate would be a five-membered ring, whose formation we think 
would be kinetically more favorable compared to a six-membered ring, as in the case of 
263 and 266.  
Scheme 3.26: Alternative to oxidation of C(2). 
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Another route that was not fully explored is the conversion of the C(2)−Si bond 
into a C(2)−O bond. Although in all our attempts the Ph−Si bond was resistant to 
cleavage under acidic conditions, there are other routes to explore. We could replace the 
phenyl group with p-anisyl, Me3Si, or Et2N115,116. Alternatively, we might treat 248 with 
PhSeCl (Scheme 3.27) to form an α-selenyl-β-silyl derivative, which in turn, upon 
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oxidation would turn into a β-silyl enone. Tamao-Fleming oxidation165 would afford the 
desired 2,4,9-triketone derivative. 
Scheme 3.27: Se-mediated oxidation of 248. 
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So far we have the bicyclo[3.3.1]nonane-4,9-dione core of nemorosone, leaving 
only the oxidation of C(2) for the completion of the skeleton. The completion of this 
synthetic project will allow us to make a valuable contribution to PPAPs chemistry. 
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3.7. Experimental Section 
For all the compounds reported, the melting points were taken on an Electrothermal 910 
and the IR data were collected on a Nicolet Magna-IR 560 spectrometer. The 400 MHz 
1H NMR and 100 MHz 13C NMR data were collected on a Varian VXR-400S. The 50 
MHz 13C NMR data were collected on a Varian Gemini 200. 
 
CO2Me
O
 
Methyl 4-allyl-7-methyl-3-oxo-6-octenoate (221).  A suspension of NaH (1.99 g, 49.36 
mmol) in dry THF (125 mL) at 0 °C was treated at 10 min intervals with methyl 3-oxo-6-
heptenoate 220 (6.99 g, 44.87 mmol), BuLi (2.32 M, 20.3 mL, 47.11 mmol), DMPU (6.0 
mL, 49.36 mmol), and prenyl bromide (5.8 mL, 49.36 mmol).  The solution was allowed 
to warm to room temperature.  The reaction was quenched with 1 M HCl, and the mixture 
was extracted with ether.  The organic portion was dried over MgSO4 and evaporated.  
Flash chromatography (15% EtOAc in petroleum ether) gave pure 221 (6.71 g, 29.95 
mmol, 67% yield).  1H NMR (400 MHz, CDCl3): δ 5.72 (m, 1H), 5.05 (m, 3H), 3.74 (s, 
3H), 3.46 (s, 2H), 2.71 (tt, 6.2 Hz, 7.7 Hz, 1H), 2.15–2.42 (m, 4H), 1.70 (s, 3H), 1.60 (s, 
3H).  Selected peaks of the enol tautomer: δ 12.0 (s, 1H), 4.89 (s, 1H). 13C NMR (400 
MHz, CDCl3): δ 205.8, 167.9, 135.6, 134.8, 121.0, 117.6, 59.2, 52.4, 49.6, 34.4, 30.0, 
26.2, 18.2.  IR (neat): 3080, 2975, 2913, 1752, 1716, 1643, 1623 cm-1.  Calcd for 
C13H20O3: C, 69.61; H, 8.99. Found: C, 69.43; H, 8.90. 
 
CO2Me
O
 
Methyl (1R*,3R)-3-allyl-6,6-dimethyl-2-cyclohexanonecarboxylate (222).  SnCl4 (3.9 
mL, 33 mmol) was added to a solution of 221 (6.71 g, 30.0 mmol) in CH2Cl2 (120 mL) at 
0 °C, and the solution was allowed to stir at room temperature overnight.  Ether (50 mL) 
was added, and the mixture was washed with 6 N HCl and water.  The organic portion 
was dried over MgSO4 and evaporated.  Flash chromatography (5% EtOAc in petroleum 
ether) gave pure 222 (5.5 g, 24.55 mmol, 82% yield).  1H NMR (400 MHz, CDCl3): δ 
5.78 (dddd, 6.4 Hz, 7.7 Hz, 10.1 Hz, 16.9 Hz, 1H), 5.0–5.08 (m, 2H), 3.72 (s, 3H), 3.34 
(s, 1H), 2.53 (m, 1H), 2.34 (m, 1H), 1.98–2.1 (m, 2H), 1.74 (m, 1H), 1.6 (m, 2H), 1.11 (s, 
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3H), 1.10 (s, 3H).  13C NMR (200 MHz, CDCl3): δ 207.0, 169.6, 136.6, 117.4, 67.4, 
52.2, 49.9, 41.1, 40.6, 34.2, 30.3, 29.4, 21.8.  IR (neat): 3076, 2951, 2866, 1751, 1709, 
1639 cm-1.   
 
CO2Me
O
OEtEtO
 
Methyl (1R*,3R)-1-(3,3-diethoxy-1-propynyl)-3-allyl-6,6-dimethyl-2- 
cyclohexanonecarboxylate (230).  A solution of 3,3-diethoxypropyne 228 (4.77 mL, 
33.14 mmol) in THF (100 mL) at -30 °C was treated at 15 min intervals with BuLi (2.32 
M, 14.3 mL, 33.14 mmol), Bu3SnCl (9.0 mL, 33.14 mmol), and a solution of 222 (5.50 g, 
24.55 mmol) in THF (10 mL).  Pb(OAc)4 (16.31 g, 36.82 mmol ) was added, and the 
mixture was allowed to warm to room temperature.  When the reaction was judged to be 
complete (TLC), water was added, and the mixture was extracted with ether.  The 
aqueous layer was neutralized with 1 M HCl (a white salt formed), and it was extracted 
with ether again.  The organic layers were combined, washed with brine, dried over 
MgSO4, and evaporated. Flash chromatography (5% EtOAc in petroleum ether) gave 230 
(4.12 g, 11.77 mmol, 53% yield) as a colorless liquid contaminated with a small amount 
of Bu3SnX.  1H NMR (400 MHz, CDCl3): δ 5.77 (m, 1H), 5.35 (s, 3H), 5.01–5.08 (m, 
2H), 3.76 (s + m, 5H), 3.63 (q, 7.15 Hz, 2H), 3.22 (ddt, Jd = 5.3 Hz, Jd = 12.5 Hz, Jt = 7.1  
Hz 1H), 2.48 (m, 1H), 2.34 (dt, Jd = 4.2 Hz, Jt = 13.6 Hz, 1H), 2.02 (m, 2H), 1.65 (m, 
1H), 1.53 (m, 1H), 1.25 (t, 7.15 Hz), 6H), 1.23 (s, 3H), 1.16 (s, 3H).  13C NMR (400 
MHz, CDCl3): δ 205.2, 167.8, 136.3, 117.4, 92.1, 85.0, 82.5, 66.9, 61.7, 53.1, 44.8, 38.0, 
34.3, 29.1, 27.0, 22.7, 15.8 (× 2).  IR (neat): 3076, 2975, 2932, 2237, 1752, 1720, 1639 
cm-1.   
CO2Me
O
CHO
 
Methyl (1R*,3R)-1-(3-oxo-1-propynyl)-3-allyl-6,6-dimethyl-2-cyclohexanone 
carboxylate (241).  HCO2H (94.16 mmol) was added to neat 230 (11.77 mmol).  The 
reaction mixture was allowed to stir overnight in the dark under N2.  Water was added, 
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and the mixture was extracted with ether.  Flash chromatography (10% EtOAc in 
petroleum ether) provided 241 (8.33 mmol, 71%) as a colorless oil.  1H NMR (400 MHz, 
CDCl3): δ 9.32 (s, 1H), 5.77 (m, 1H), 5.03-5.11 (m, 2H), 3.8 (s, 3H), 3.11 (m, 1H), 2.5 
(m, 1H), 2.28 (dt, Jt = 13.7 Hz, Jd = 4.3 Hz, 1H), 2.01-2.09 (m, 2H), 1.57 (m, 1H), 1.43 
(ddd, Jd = 14.3 Hz, Jd = 4.4 Hz, Jd = 2.56 Hz, 1H), 1.25 (s, 3H), 1.2 (s, 3H).  13C NMR 
(400 MHz, CDCl3): δ 203.2, 176.9, 166.5, 135.8, 117.9, 93.2, 88.0, 67.6, 53.6, 45.5, 45.0, 
37.9, 34.3, 29.0, 27.1, 22.8.  IR (neat): 3076, 2952, 2878, 2206, 1755, 1724, 1670, 1456, 
1437 cm-1.   
CO2Me
O
O
SiEt3
H
 
 
Methyl (1R*,3R,E)-1-(2-triethylsilyl-3-oxo-1-propenyl)-3-allyl-6,6-dimethyl-2-cyclo 
hexanonecarboxylate (244).  Co2(CO)8 (3.4 g, 10 mmol) was added to a solution of 241 
(2.30 g, 8.33 mmol) in CH2Cl2 (32 mL) at 0 °C.  After about 2 h, the solvent was 
evaporated.  The residue was filtered through a short column of silica gel, eluting with 
hexane (the brown eluant was discarded) and then 30% EtOAc in petroleum ether.  The 
solvent was evaporated to give the Co2(CO)6 complex of 241 (4.06 g, 7.21 mmol, 87% 
yield) as a dark red oil.   
 The complex (4.00 g, 7.09 mmol) was redissolved in dry CH2Cl2 (40 mL), and 
bis(trimethylsilyl)acetylene 243 (2.42 g, 14.2 mmol) and triethylsilane (6.4 mL, 40 
mmol) were added.  The mixture was allowed to stir at 65 °C for 3 h (monitored by 
TLC).  The solvent was evaporated, and the residue was filtered through a short column 
of silica gel, eluting with hexane (the brown eluant was discarded) and then 30% EtOAc 
in petroleum ether.  The solvent was evaporated to provide 244 (2.61 g, 6.66 mmol, 94% 
yield) as a colorless liquid.  1H NMR (400 MHz, CDCl3): δ 9.87 (s, 1H), 6.87 (s, 1H), 
5.68 (m, 1H), 5.01 (m, 2H), 3.69 (s, 3H), 2.68 (dq, Jd = 6.4 Hz, Jq = 12.5 Hz, 1H), 2.48 
(m, 1H), 1.98 (m, 3H), 1.62 (m, 1H), 1.49 (m, 1H), 1.20 (s, 3H), 1.14 (s, 3H), 0.92 (t, 7.9 
Hz, 9H), 0.73 (m, 6H). 13C NMR (400 MHz, CDCl3): δ 207.8, 196.4, 169.2, 150.9, 146.7, 
136.2, 117.7, 71.9, 52.7, 47.1, 43.2, 37.1, 34.4, 29.0, 26.1, 24.9, 7.9 (× 3), 3.7 (× 3). IR 
(neat): 2734, 2206, 1751, 1713, 1666, 1573, 1456 cm- 1. Calcd for C22H36O4Si: C, 67.30; 
H, 9.24. Found: C, 67.34; H, 8.82. 
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Methyl (1R*,4S,5R)- and (1R*,4R,5R)-3-triethylsilyl-4-hydroxy-5-allyl-8,8-dimethyl 
bicyclo[3.3.1]non-2-en-9-one-1-carboxylate (245a and 245b).  Twenty drops of 6 M 
HCl were added to a solution of 244 (2.61 g, 6.66 mmol) in THF (25 mL).  After 4.5 h 
(monitored by TLC), water was added.  The aqueous layer was extracted with ether (2 × 
30 mL), and the combined organic layers were washed with brine, dried over MgSO4, 
and evaporated.  Flash chromatography (8% EtOAc in petroleum ether) provided 245a 
(endo OH) and 245b (exo OH) (combined 4.77 mmol, 72% yield).   
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CO2Me
O
HO
SiEt3
 
Compound 245a. 1H NMR (400 MHz, CDCl3): δ 6.04 (m + d, 1.8 Hz, 2H), 5.15 (m, 2H), 
4.42 (d, 4.6 Hz, 1H), 3.75 (s, 3H), 2.40 (dd, 8.8 Hz, 14.0 Hz, 1H), 2.32 (dddd, 14.0 Hz, 
6.6 Hz, 1.5 Hz, 1.3 Hz, 1H), 2.24 (ddd, 14.1 Hz, 6.1 Hz, 2.0 Hz, 1H), 2.00 (dt, Jd = 4.6 
Hz, Jt = 13.8 Hz, 1H), 1.91 (d, 6.0 Hz, 1H), 1.62 (ddt, Jd = 0.9 Hz, Jd = 5.3 Hz, Jt = 14.1 
Hz, 1H), 1.26 (s, 3H), 1.20 (s, 3H), 1.15 (ddd, 2.0 Hz, 5.1 Hz, 13.7 Hz, 1H), 0.97 (t, 7.8 
Hz, 9H), 0.72 (m, 6H). 13C NMR (400 MHz, CDCl3): δ 212.5, 171.0, 142.4, 137.2, 136.6, 
118.9, 80.7, 68.3, 56.3, 52.5, 43.6, 40.7, 36.4, 29.1, 25.8, 23.6, 8.1 (⋅ 3), 4.1 (×3). IR 
(KBr): 3491, 1744, 1689, 1612 cm- 1. Calcd for C22H36O4Si: C, 67.30; H, 9.24. Found: C, 
67.39; H, 8.81. 
CO2Me
O
HO
SiEt3
 
Compound 245b. 1H NMR (400 MHz, CDCl3): δ 6.13 (s, 1H), 5.80 (dddd, 6.8 Hz, 8.1 
Hz, 10.3 Hz, 16.8 Hz, 1H), 5.15 (m, 2H), 4.23 (s, 1H), 3.69 (s, 3H), 2.51 (dd, 8.2 Hz, 
14.1 Hz, 1H), 2.32 (ddt, Jd = 6.1 Hz, Jd = 14.1 Hz, Jt = 1.3 Hz, 1H), 1.84 (m, 2H), 1.67 
(m, 1H), 1.30 (broad, 1H), 1.17 (s, 3H), 0.98 (s, 3H), 0.95 (m + t, 8.0 Hz, 10H), 0.68 (q, 
8.0 Hz, 6H). 13C NMR (400 MHz, CDCl3): δ 211.2, 170.8, 141.6, 140.8, 134.7, 119.3, 
82.4, 69.0, 54.0, 52.7, 42.6, 37.9, 36.5, 32.2, 26.3, 23.4, 8.0 (× 3), 3.8 (× 3). IR (neat): 
3522, 1752, 1713, 1608 cm- 1. Calcd for C22H36O4Si: C, 67.30; H, 9.24. Found: C, 66.98; 
H, 8.86. 
Methyl (1R*,4S,5R)- and (1R*,4R,5R)-4-hydroxy-5-allyl-8,8-dimethyl 
bicyclo[3.3.1]non-2-en-9-one-1-carboxylate (246a and 246b). To a solution of 245a,b 
(0.46 g, 1.17 mmol) in 6 mL CH3CN it was added TBAF (1M THF) (3.51 mL, 3.51 
mmol). The mixture was allowed to stir under reflux for six hours. The reaction mixture 
was poured into water and extracted with ether three times. The combined organic layers 
were washed with brine, dried over MgSO4, and evaporated.  Flash chromatography 
(18% EtOAc in petroleum ether) provided 246a (endo OH) and 246b (exo OH) 
(combined 0.29 g, 1.04 mmol, 89% yield).   
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CO2Me
O
HO
 
 
Compound 246a. mp: 87 ºC. 1H NMR (400 MHz, CDCl3): δ 5.98 (m + dd, 2.4 Hz, 10.1 
Hz, 2H), 5.91 (dd, 1.6 Hz, 10.1 Hz, 1H), 5.10 (m, 2H), 4.39 (s, broad, 1H), 3.71 (s, 3H), 
2.39 (dd, 8.6 Hz, 13.9 Hz, 1H), 2.30 (dd~t, 6.41 Hz, 13.9 Hz, 1H), 2.23 (ddd, 2.0 Hz, 4.9 
Hz, 13.9 Hz, 1H), 2.01 (dt, Jd = 4.8 Hz, Jt = 13.9 Hz, 1H), 1.61 (dt, Jd = 5.3 Hz, Jt = 14.3 
Hz, 1H), 1.25 (s, 3H), 1.14 (ddd, 2.0 Hz, 5.3 Hz, 14.1 Hz, 1H), 0.98 (s, 3H). 13C NMR 
(400 MHz, CDCl3):  δ 208.3, 171.0, 136.5, 132.8, 129.0, 119.4, 76.7, 67.3, 56.2, 53.0, 
43.6, 43.6, 40.9, 36.5, 29.2, 26.0, 24.0. IR (neat): 3481, 3083, 1748, 1701cm- 1. Calcd for 
C16H22O4: C, 69.04; H, 7.97. Found: C, 69.48; H, 7.66. 
 
CO2Me
O
HO
 
Compound 246b. Selected 1H NMR data (400 MHz, CDCl3): δ 6.20 (dd, 4.4 Hz, 9.7 Hz, 
1H), 4.28 (d, 4.3 Hz, 1H), 3.75 (s, 3H), 2.63 (dd~t, 7.89 Hz, 14.1 Hz, 1H). 
 
CO2Me
O
O
 
Methyl (1R*,5R)-5-allyl-8,8-dimethylbicyclo[3.3.1]non-2-en-4,9-dione-1-carboxylate 
(247). To a solution of 246a,b (1.04 mmol, 0.29 g) in 11 mL dry CH2Cl2 was added 
NMO (2.60 mmol, 0.30 g), crushed molecular sieves (4Å) and TPAP (0.056 mmol, 0.020 
g), in this order. The mixture was allowed to stir at room temperature for one hour 
(monitored by TLC), and then it was filtered through a short column of silica gel and 
eluted with 18% EtOAc in petroleum ether. After the solvent was evaporated, pure 247 
was obtained (0.091 mmol, 0.250 g, 87% yield). mp: 95 ºC. 1H NMR (400 MHz, CDCl3): 
δ 7.19 (d, Jd = 10.1 Hz , 1H), 6.47 (d, Jd = 10.1 Hz , 1H), 5.79 (m, 1H), 5.09 (m, 2H), 
3.79 (s, 3H), 2.57 (ddt, Jt = 1.3 Hz, Jd = 7.8 Hz, Jd = 14.3 Hz, 1H), 2.49 (dd~t, 6.41 Hz, 
13.9 Hz, 1H), 2.01 (dd, 4.4 Hz, 3.2 Hz), 1.97 (dt, Jd = 4.4 Hz, Jt = 13.2 Hz, 1H), 1.80 
(dm, 14.5 Hz, 1H), 1.70 (m, 1H), 1.31 (s, 3H), 1.27 (m, 1H), 1.07 (s, 3H).  13C NMR 
(400 MHz, CDCl3): δ 203.7, 199.1, 168.8, 147.2, 134.0, 131.8, 119.0, 68.5, 65.3, 52.8, 
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41.9, 35.3, 34.8, 34.1, 26.4, 23.0.  IR (neat): 3072, 3007, 1752, 1720, 1679cm-1.  Calcd 
for C16H20O4: C, 69.54; H, 7.30. Found: C, 69.26; H, 7.30. 
 
CO2Me
O
O SiMe2Ph
 
Methyl (1R*,2R,5R)-5-allyl-8,8-dimethyl-2-(dimethylphenylsilyl)bicyclo[3.3.1]non-
4,9-dione-1-carboxylate (248). PhMe2SiCl (4.10 mL, 24.2 mmol) was added to a 
solution of Li (0.41 g, 57.7 mmol) in 15 mL dry THF at 0 ºC. After about six hours, the 
mixture was added to a slurry of CuI (2.35 g, 12.1 mmol) in 10 mL dry THF under N2, at 
-30 ºC. Enone 247 (0.477 g, 1.73 mmol) was added after four more hours, and the 
mixture was allowed to stir overnight at room temperature. The reaction mixture was 
quenched with 1 N HCl and extracted with ether three times. The combined organic 
layers were washed with brine, dried over MgSO4, and evaporated.  Flash 
chromatography (10% EtOAc in petroleum ether) provided 248 (0.57 g, 1.39 mmol, 80% 
yield). mp: 154 ºC. 1H NMR (400 MHz, CDCl3): δ 7.47 (m , 2H), 7.35 (m , 3H), 5.75 (m, 
1H), 5.00 (m, 2H), 3.72 (s, 3H), 2.47 (dd, 13.5 Hz, 2.9 Hz, 1H), 2.41 (dd, 13.4 Hz, 6.2 
Hz, 1H), 2.24 (dd, 13.4 Hz, 8.4 Hz, 1H), 2.15 (m, 1H), 2.05 (m, 1H, 1.70 (m, 3H), 1.51 
(s, 1H), 1.22 (s, 3H), 1.21 (s, 3H), 1.08 (m, 1H), 0.34 (s, 3H), 0.26 (s, 3H).  13C NMR 
(400 MHz, CDCl3): δ 210.2, 209.4, 171.9, 139.3, 134.3, 133.3, 130.1, 128.8, 119.6, 67.2, 
64.9, 52.1, 45.1, 44.2, 37.8, 36.3, 35.7, 26.1, 23.5, 23.4, -2.0, -4.6.  IR (neat): 3068, 1748, 
1728, 1699, 1426, 1388, 1107 cm-1.  Calcd for C24H32O4Si: C, 69.86; H, 7.82. Found: C, 
68.72; H, 7.60. 
 
CO2Me
O
O O
 
Methyl (1R*,2R,3S,5R)-5-allyl-8,8-dimethyl-2-oxa -bicyclo[3.3.1]non-4,9-dione-1-
carboxylate (254). Enone 247 (0.262 g, 1.00 mmol) was dissolved in 10 mL MeOH and 
a few drops of CH2Cl2.  30% H2O2 (0.67 mL) followed by KHCO3 (0.024 g, 0.024 mmol) 
were added and the reaction mixture was allowed to stir overnight. After the evaporation 
of the solvent, a white solid was formed which was dissolved in 20% EtOAc in pet ether. 
Flash chromatography (20% EtOAc in petroleum ether) provided 254 (0.186 g, 0.640 
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mmol, 64% yield). mp: 109 ºC. 1H NMR (400 MHz, CDCl3): δ 5.70 (m, 1H), 5.00-5.08 
(m, 2H), 4.00 (d, 3.7 Hz, 1H), 3.87 (s, 3H), 3.71 (d, 3.5 Hz, 1H), 2.47 (m, 2H), 1.95 (m, 
3H), 1.4 (m, 1H), 1.23 (s, 3H), 1.22 (s, 3H).  13C NMR (400 MHz, CDCl3): δ 205.8, 
200.0, 168.5, 133.5, 119.4, 67.1, 63.7, 57.5, 55.8, 53.2, 43.3, 38.7, 36.5, 36.0, 27.1, 25.7. 
IR (neat): 3081, 1753, 1720, 1704, 1234 cm-1.  Calcd for C16H20O5: C, 65.74; H, 6.90. 
Found: C, 65.43; H, 6.92. 
 
O
O
O
N
N
 
5-Allyl-8,8-dimethyl-1-(pyrazole-1-carbonlyl)-bicyclo[3.3.1]none-2-ene-4,9-dione 
(263). To a solution of triol 260 (0.15 g, 0.59 mmol) in 6 mL acetone at 0 ºC it was added 
Jones reagent – CrO3 (0.6 g, 6.0 mmol) and H2SO4 (0.5 mL) – and the reaction mixture 
was allowed to stir at room temperature for 7 hours (monitored by TLC). After addition 
of isopropanol, the mixture was extracted with CH2Cl2 three times. The combined 
organic layers were washed with brine, dried over MgSO4, and evaporated. The crude 
residue was dissolved in 1 mL (COCl)2 and two drops of DMF. After approximatively 20 
minutes, the remaining (COCl)2 was evaporated and the crude residue was dissolved in 3 
mL dry CH2Cl2. Pyrazole (0.041 g, 0.60 mmol) was added followed by NEt3 (62.0 μL, 
6.0 mmol). The reaction mixture was quenched with 1 N HCl and extracted with ether 
three times. The combined organic layers were washed with brine, dried over MgSO4, 
and evaporated.  Flash chromatography (10% EtOAc in petroleum ether) provided 263 
(0.09 g, 0.30 mmol, 50% yield over three steps). 1H NMR (400 MHz, CDCl3): δ 8.21 (d, 
2.9 Hz, 1H), 7.46 (d, 1.5 Hz, 1H), 6.98 (d, 10.0 Hz, 1H), 6.49 (d, 10.0 Hz, 1H), 6.37 (dd, 
1.5 Hz, 2.9 Hz, 1H), 6.73 (m, 1H), 5.10 (m, 2H), 2.60 (m, 2H), 1.88 (m, 3H), 1.39 (s, 
3H), 1.31 (s, 3H), 1.25 (m, 1H).  13C NMR (400 MHz, CDCl3): δ 205.3, 199.5, 167.5, 
146.8, 143.7, 134.4, 129.9, 129.5, 118.4, 110.0, 67.7, 66.3, 44.5, 37.6, 35.9, 34.7, 26.4, 
22.2. 
 
O
HO
O
N
N
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(4R)-5-Allyl-4-hydroxy-8,8-dimethyl-1-(pyrazole-1-carbonyl)-bicyclo[3.3.1]non-2-
en-9-one (266). The enone 263 (0.09 g, 0.30 mmol) was dissolved in 1 mL MeOH and a 
few drops of dry THF. CeCl3·H2O (0.11 g, 0.30 mmol) was added followed byNaBH4 
(0.011 g, 0.300 mmol). After about 1 hour (monitored by TLC), the reaction mixture was 
quenched with 1 N HCl and extracted with ether three times. The combined organic 
layers were washed with brine, dried over MgSO4, and evaporated.  Flash 
chromatography (30% EtOAc in petroleum ether) provided 266 (0.03 g, 0.1 mmol, 30% 
yield). Selected 1H NMR data (400 MHz, CDCl3): δ 8.20 (dd, 1.7 Hz, 2.9 Hz, 1H), 7.45 
(dd, 0.7 Hz, 1.5 Hz, 1H), 6.36 (dd, 1.5 Hz, 3.0 Hz, 1H), 6.03 (dd, 2.6 Hz, 10.1 Hz, 1H), 
5.97 (m, 1H),  5.77 (dd, 2.2 Hz, 10.1 Hz, 1H), 5.15 (m, 2H), 4.7 (t, 2.0 Hz, 1H). 13C 
NMR (400 MHz, CDCl3): δ 208.7, 169.2, 143.3, 136.4, 131.2, 129.6, 126.9, 118.6, 
109.3, 74.1, 66.0, 56.2, 46.1, 39.7, 36.4, 31.6, 25.3, 22.3. 
 
O
O
O
N
N
AcO
 
Attempted oxidation of 263: 263 (0.08 g, 0.26 mmol), PhI(OAc)2 (0.17 g, 0.52 mmol), 
and Pd(OAc)2 (0.001 g, 0.010 mmol) were dissolved in 2 mL CH3CN. The reaction 
mixture was allowed to stir for two days at 75 ºC. After cooling, the mixture was filtered 
though a short silica column. Selected 1H NMR data (400 MHz, CDCl3): δ 8.24 (dd, 0.7 
Hz, 2.9 Hz, 1H), 6.97 (d, 10.1 Hz, 1H), 6.50 (d, 10.1 Hz, 1H), 6.40 (d, 16.0 Hz, 1H), 6.33 
(dd, 1.46, 2.9 Hz), 6.18 (m, 1H), 1.41 (s, 3H), 1.33 (s, 3H), 1.26 (s, 3H). 
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Chapter 4. Conclusion 
 
The aim of my research was to synthesize nemorosone, a natural product with 
antibacterial, antioxidant and anticancer activities, which is found in the resins and latex 
of plants of Clusia (Clusiaceae) species. Structurally, nemorosone is a polycyclic 
polyprenylated acylphloroglucinol (PPAP), a class of compounds that reveal intriguing 
biological activities and interesting and challenging chemical structures.  
In the past decade many approaches to the synthesis of the bicyclo[3.3.1]nonane-
2,4,9-trione structure of type A PPAPs have been reported, but only two total syntheses 
of any PPAP, garsubellin A by Shibasaki and Danishefsky, have been published recently, 
near the end of 2005.  All approaches have relied on the α,α´-annulation of a three-carbon 
bridge onto a cyclohexanone, although the methods used to execute this annulation differ 
dramatically.   
We have developed a short and efficient synthetic approach to the 
bicyclo[3.3.1]nonane skeleton of the PPAPs that involves a novel three-carbon α,α´-
annulation of a sterically hindered cyclic β-keto ester with 3,3-diethoxypropyne. The 
alkynylation reaction permits the construction of the two contiguous quaternary centers 
of the PPAPs in reasonable yield and without complications from side reactions. We have 
also successfully applied a recently developed syn hydrosilylation to the very hindered 
product of this alkynylation reaction. 
Once the total synthesis of nemorosone is completed and our methodology will 
prove to be successful, we can apply it to other compounds from this class, and in the 
long run, chemists will be able to evaluate and understand the relationships between the 
molecular structure and the biological activity.  
The total synthesis of nemorosone is important not only because of the reasons 
above mentioned but also because of the opportunity to boost the limits of organic 
chemistry. Our methodology received positive feedback already, and we see this total 
synthesis of nemorone as an ideal platform for the implementation of new synthetic 
methodologies. 
 In conclusion, studies toward synthesis of this class of compounds have emerged 
in the past decade. We have competed successfully with renowned organic chemists from 
all around the world. We have achieved already, through a unique methodology, the 
backbone of our targeted natural product and our future plan is to complete its total 
synthesis. 
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Appendix 
 
Table A.1: Crystal data and structure refinement for 237a. 
Refinement method for all structures is full-matrix least-
square on F2. 
Empirical formula  
Formula weight  
Temperature  
Wavelength (Å) 
Crystal system 
Space group  
Unit cell dimensions  
a (Å)  
α (°) 
b (Å)  
β (°) 
c (Å)  
γ (°) 
Volume (Å3) 
Z 
Calculated density (Mg/m3) 
Absorption coefficient (mm–1) 
F(000)  
Crystal size (mm) 
Θ range for data collection (°) 
Limiting indices  
 
 
Reflections collected / unique  
 
Completeness to Θ= 27.46  
C22H36O4Si 
392.60 
90.0(2) K 
0.71073  
Monoclinic 
C2/c 
 
19.1880(3) 
90 
9.48600(10) 
90.6760(7) 
24.8430(4) 
90 
4521.54(11) 
8 
1.153 
0.127 
1712 
0.22 × 0.20 × 0.20 
1.64 to 27.46 
-24≤h≤24 
-11≤k≤12 
32≤l≤32 
9375 / 5163  
[R(int) = 0.0411] 
99.9 % 
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Absorption correction  
Max. transmission 
Min. transmission  
Data / restraints / parameters  
Goodness-of-fit on F2  
Final R indices [I>2σ(I)]  
 
R indices (all data)  
 
Largest diff. peak and hole 
(e·Å–3) 
 
None 
0.9751  
0.9727 
5163 / 0 / 251 
1.472 
R1 = 0.0496 
ωR2 = 0.1198 
R1 = 0.0869 
ωR2 = 0.1353 
0.539 and -0.248 
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Table A.2: Atomic coordinates ( x 104) and equivalent 
isotropic displacement parameters (A2 x 103) for 237a. U(eq) 
is defined as one third of the trace of the orthogonalized 
Uij tensor. 
 x y z U(eq) 
Si(1) 
C(1) 
C(2) 
C(3) 
O(4) 
C(4) 
C(5) 
C(6) 
C(7) 
C(8) 
O(9) 
C(9) 
C(10) 
C(11) 
O(12) 
C(12) 
O(13) 
C(13) 
C(14) 
C(15) 
C(16) 
C(17) 
C(18) 
C(19) 
C(20) 
C(21) 
C(22) 
 
4212(1) 
2153(1) 
2913(1) 
3289(1) 
3192(1) 
2998(1) 
2194(1) 
1768(1) 
1819(1) 
1656(1) 
1815(1) 
2025(1) 
1794(1) 
 888(1) 
1582(1) 
2048(1) 
2572(1) 
2494(1) 
2027(1) 
1268(1) 
 935(1) 
4525(1) 
4640(1) 
4780(1) 
5565(1) 
4241(1) 
3829(1) 
 
4763(1) 
3056(2) 
3465(2) 
4267(2) 
6200(1) 
4759(2) 
4545(2) 
5692(2) 
5618(2) 
4154(2) 
2113(1) 
3132(2) 
4165(2) 
3784(2) 
1066(1) 
1532(2) 
 728(1) 
-775(2) 
4568(2) 
4480(2) 
5417(2) 
3620(2) 
2060(2) 
4504(3) 
4602(3) 
6623(2) 
6885(3) 
 
1175(1) 
1100(1) 
1021(1) 
1354(1) 
1952(1) 
1887(1) 
1955(1) 
1653(1) 
1041(1) 
 811(1) 
1956(1) 
1706(1) 
 205(1) 
 905(1) 
 646(1) 
 918(1) 
1114(1) 
1030(1) 
2561(1) 
2697(1) 
2982(1) 
 610(1) 
 737(1) 
1783(1) 
1678(1) 
 926(1) 
 400(1) 
 
21(1) 
14(1) 
15(1) 
16(1) 
24(1) 
16(1) 
15(1) 
17(1) 
18(1) 
16(1) 
18(1) 
14(1) 
22(1) 
21(1) 
24(1) 
16(1) 
19(1) 
23(1) 
18(1) 
23(1) 
35(1) 
23(1) 
30(1) 
32(1) 
45(1) 
40(1) 
48(1) 
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Table A.3: Bond lengths [Å] and angles [°] for 237a. 
Si(1)-C(19)  
Si(1)-C(21)  
Si(1)-C(17)  
Si(1)-C(3)  
C(1)-C(2)  
C(1)-C(12)  
C(1)-C(9) 
C(1)-C(8)  
C(2)-C(3)  
C(2)-H(2)  
C(3)-C(4)  
O(4)-C(4)  
O(4)-H(4)  
C(4)-C(5)  
C(4)-H(4A)  
C(5)-C(9)  
C(5)-C(14)  
C(5)-C(6) 
C(6)-C(7)  
C(6)-H(6A)  
C(6)-H(6B)  
C(7)-C(8)  
C(7)-H(7A)  
C(7)-H(7B)  
C(8)-C(10) 
C(8)-C(11)  
O(9)-C(9)) 
C(10)-H(10A)  
C(10)-H(10B)  
C(10)-H(10C)  
C(11)-H(11A)  
C(11)-H(11B)  
C(11)-H(11C)  
O(12)-C(12)  
C(12)-O(13)  
O(13)-C(13) 
C(13)-H(13A)  
C(13)-H(13B)  
C(13)-H(13C)  
C(14)-C(15) 
C(14)-H(14A)  
C(14)-H(14B)  
C(15)-C(16)  
C(15)-H(15)  
C(16)-H(16A)  
C(16)-H(16B)  
1.8679(19) 
1.871(2) 
1.8772(19) 
1.8905(17) 
1.524(2) 
1.526(2) 
1.532(2) 
1.579(2) 
1.331(2) 
0.9500 
1.516(2) 
1.425(2) 
0.8400 
1.569(2) 
1.0000 
1.509(2) 
1.543(2) 
1.549(2) 
1.528(2) 
.9900 
0.9900 
1.533(2) 
0.9900 
0.9900 
1.531(2) 
1.535(2) 
1.220(2) 
0.9800 
0.9800 
0.9800 
0.9800 
0.9800 
0.9800 
1.1999(19) 
1.347(2) 
1.448(2) 
0.9800 
0.9800 
0.9800 
1.502(2) 
0.9900 
0.9900 
1.309(3) 
0.9500 
0.9500 
0.9500 
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C(17)-C(18)  
C(17)-H(17A)  
C(17)-H(17B)  
C(18)-H(18A)  
C(18)-H(18B)  
C(18)-H(18C)  
C(19)-C(20)  
C(19)-H(19A)  
C(19)-H(19B)  
C(20)-H(20A)  
C(20)-H(20B)  
C(20)-H(20C)  
C(21)-C(22)  
C(21)-H(21A)  
C(21)-H(21B)  
C(22)-H(22A)  
C(22)-H(22B)  
C(22)-H(22C)  
C(19)-Si(1)-C(21)  
C(19)-Si(1)-C(17)  
C(21)-Si(1)-C(17)  
C(19)-Si(1)-C(3)  
C(21)-Si(1)-C(3)  
C(17)-Si(1)-C(3)  
C(2)-C(1)-C(12)  
C(2)-C(1)-C(9)  
C(12)-C(1)-C(9) 
C(2)-C(1)-C(8) 
C(12)-C(1)-C(8)  
C(9)-C(1)-C(8)  
C(3)-C(2)-C(1)  
C(3)-C(2)-H(2)  
C(1)-C(2)-H(2)  
C(2)-C(3)-C(4) 
C(2)-C(3)-Si(1) 
C(4)-C(3)-Si(1) 
C(4)-O(4)-H(4)  
O(4)-C(4)-C(3) 
O(4)-C(4)-C(5)  
C(3)-C(4)-C(5) 
O(4)-C(4)-H(4A)  
C(3)-C(4)-H(4A)  
C(5)-C(4)-H(4A)  
C(9)-C(5)-C(14) 
C(9)-C(5)-C(6)  
C(14)-C(5)-C(6) 
C(9)-C(5)-C(4)  
1.529(3) 
0.9900 
0.9900 
0.9800 
0.9800 
0.9800 
1.535(3) 
0.9900 
0.9900 
0.9800 
0.9800 
0.9800 
1.539(3) 
0.9900 
0.9900 
0.9800 
0.9800 
0.9800 
111.87(11) 
109.88(9) 
106.64(10) 
108.38(8) 
110.11(9) 
109.95(8) 
109.06(14) 
106.16(13) 
108.24(14) 
110.29(14) 
114.48(13) 
108.26(14) 
125.37(16) 
117.3 
117.3 
121.10(15) 
119.89(13) 
118.99(12) 
109.5 
107.21(14) 
111.60(14) 
115.29(14) 
107.5 
107.5 
107.5 
111.50(15) 
108.50(13) 
110.40(14) 
106.09(14) 
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C(14)-C(5)-C(4) 
C(6)-C(5)-C(4)  
C(7)-C(6)-C(5)  
C(7)-C(6)-H(6A)  
C(5)-C(6)-H(6A)  
C(7)-C(6)-H(6B)  
C(5)-C(6)-H(6B)  
H(6A)-C(6)-H(6B)  
C(6)-C(7)-C(8) 
C(6)-C(7)-H(7A)  
C(8)-C(7)-H(7A)  
C(6)-C(7)-H(7B)  
C(8)-C(7)-H(7B)  
H(7A)-C(7)-H(7B)  
C(10)-C(8)-C(7) 
C(10)-C(8)-C(11)  
C(7)-C(8)-C(11)  
C(10)-C(8)-C(1) 
C(7)-C(8)-C(1)  
C(11)-C(8)-C(1)  
O(9)-C(9)-C(5)  
O(9)-C(9)-C(1)  
C(5)-C(9)-C(1) 
C(8)-C(10)-H(10A)  
C(8)-C(10)-H(10B)  
H(10A)-C(10)-H(10B)  
C(8)-C(10)-H(10C)  
H(10A)-C(10)-H(10C)  
H(10B)-C(10)-H(10C)  
C(8)-C(11)-H(11A)  
C(8)-C(11)-H(11B)  
H(11A)-C(11)-H(11B)  
C(8)-C(11)-H(11C)  
H(11A)-C(11)-H(11C)  
H(11B)-C(11)-H(11C)  
O(12)-C(12)-O(13)  
O(12)-C(12)-C(1)  
O(13)-C(12)-C(1)  
C(12)-O(13)-C(13)  
O(13)-C(13)-H(13A)  
O(13)-C(13)-H(13B)  
H(13A)-C(13)-H(13B)  
O(13)-C(13)-H(13C)  
H(13A)-C(13)-H(13C)  
H(13B)-C(13)-H(13C)  
C(15)-C(14)-C(5)  
C(15)-C(14)-H(14A)  
108.57(13) 
111.72(14) 
114.23(15) 
108.7 
108.7 
108.7 
108.7 
107.6 
113.44(15) 
108.9 
108.9 
108.9 
108.9 
107.7 
108.87(14) 
109.15(14) 
110.04(14) 
109.92(14) 
108.01(13) 
110.83(14) 
124.44(15) 
121.41(16) 
114.15(14) 
109.5 
109.5 
109.5 
109.5 
109.5 
109.5 
109.5 
109.5 
109.5 
109.5 
109.5 
109.5 
122.87(17) 
127.55(16) 
109.57(14) 
115.50(13) 
109.5 
109.5 
109.5 
109.5 
109.5 
109.5 
115.49(14) 
108.4 
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C(5)-C(14)-H(14A)  
C(15)-C(14)-H(14B)  
C(5)-C(14)-H(14B)  
H(14A)-C(14)-H(14B)  
C(16)-C(15)-C(14)  
C(16)-C(15)-H(15)  
C(14)-C(15)-H(15)  
C(15)-C(16)-H(16A)  
C(15)-C(16)-H(16B)  
H(16A)-C(16)-H(16B)  
C(18)-C(17)-Si(1)  
C(18)-C(17)-H(17A)  
Si(1)-C(17)-H(17A)  
C(18)-C(17)-H(17B)  
Si(1)-C(17)-H(17B)  
H(17A)-C(17)-H(17B)  
C(17)-C(18)-H(18A)  
C(17)-C(18)-H(18B)  
H(18A)-C(18)-H(18B)  
C(17)-C(18)-H(18C)  
H(18A)-C(18)-H(18C)  
H(18B)-C(18)-H(18C)  
C(20)-C(19)-Si(1)  
C(20)-C(19)-H(19A)  
Si(1)-C(19)-H(19A)  
C(20)-C(19)-H(19B)  
Si(1)-C(19)-H(19B)  
H(19A)-C(19)-H(19B)  
C(19)-C(20)-H(20A)  
C(19)-C(20)-H(20B)  
H(20A)-C(20)-H(20B)  
C(19)-C(20)-H(20C)  
H(20A)-C(20)-H(20C)  
H(20B)-C(20)-H(20C)  
C(22)-C(21)-Si(1)  
C(22)-C(21)-H(21A)  
Si(1)-C(21)-H(21A)  
C(22)-C(21)-H(21B)  
Si(1)-C(21)-H(21B)  
H(21A)-C(21)-H(21B)  
C(21)-C(22)-H(22A)  
C(21)-C(22)-H(22B)  
H(22A)-C(22)-H(22B)  
C(21)-C(22)-H(22C)  
H(22A)-C(22)-H(22C)  
H(22B)-C(22)-H(22C)  
 
108.4 
108.4 
108.4 
107.5 
124.36(19) 
117.8 
117.8 
120.0 
120.0 
120.0 
116.84(13) 
108.1 
108.1 
108.1 
108.1 
107.3 
109.5 
109.5 
109.5 
109.5 
109.5 
109.5 
114.73(14) 
108.6 
108.6 
108.6 
108.6 
107.6 
109.5 
109.5 
109.5 
109.5 
109.5 
109.5 
114.64(16) 
108.6 
108.6 
108.6 
108.6 
107.6 
109.5 
109.5 
109.5 
109.5 
109.5 
109.5 
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Table A.4: Anisotropic displacement parameters (Å2 x 103) 
for 237a. The anisotropic displacement factor exponent 
takes the form: -2 π2 [h2 a*2 U11 + ... + 2 h k a* b* U12] 
 U11 U22 U33 U23 U13 U12 
Si(1) 
C(1) 
C(2) 
C(3) 
O(4) 
C(4) 
C(5) 
C(6) 
C(7) 
C(8) 
O(9) 
C(9) 
C(10) 
C(11) 
O(12) 
C(12) 
O(13) 
C(13) 
C(14) 
C(15) 
C(16) 
C(17) 
C(18) 
C(19) 
C(20) 
C(21) 
C(22) 
16(1) 
17(1) 
16(1) 
18(1) 
28(1) 
18(1) 
18(1) 
19(1) 
21(1) 
18(1) 
21(1) 
9(1) 
30(1) 
17(1) 
26(1) 
19(1) 
22(1) 
33(1) 
22(1) 
24(1) 
31(1) 
17(1) 
30(1) 
20(1) 
21(1) 
29(1) 
62(2) 
24(1) 
14(1) 
15(1) 
15(1) 
21(1) 
16(1) 
16(1) 
15(1) 
15(1) 
16(1) 
17(1) 
17(1) 
21(1) 
20(1) 
19(1) 
18(1) 
13(1) 
13(1) 
20(1) 
29(1) 
40(2) 
33(1) 
35(1) 
51(2) 
78(2) 
28(1) 
33(1) 
22(1) 
12(1) 
15(1) 
15(1) 
22(1) 
15(1) 
12(1) 
18(1) 
17(1) 
16(1) 
16(1) 
16(1) 
15(1) 
26(1) 
26(1) 
11(1) 
21(1) 
24(1) 
12(1) 
17(1) 
36(1) 
19(1) 
25(1) 
24(1) 
37(1) 
64(2) 
51(2) 
-2(1) 
0(1) 
-1(1) 
-1(1) 
-8(1) 
-2(1) 
0(1) 
-2(1) 
2(1) 
2(1) 
4(1) 
1(1) 
2(1) 
0(1) 
-3(1) 
0(1) 
-1(1) 
0(1) 
-4(1) 
-2(1) 
-9(1) 
1(1) 
-5(1) 
-5(1) 
-1(1) 
-2(1) 
21(1) 
4(1) 
0(1) 
3(1) 
1(1) 
5(1) 
0(1) 
1(1) 
2(1) 
1(1) 
1(1) 
2(1) 
-1(1) 
-3(1) 
-3(1) 
-7(1) 
4(1) 
-1(1) 
3(1) 
2(1) 
4(1) 
10(1) 
2(1) 
-3(1) 
-1(1) 
-3(1) 
19(1) 
28(1) 
-4(1) 
-1(1) 
2(1) 
2(1) 
-8(1) 
-5(1) 
0(1) 
2(1) 
2(1) 
3(1) 
-2(1) 
2(1) 
0(1) 
2(1) 
-3(1) 
2(1) 
2(1) 
2(1) 
-1(1) 
3(1) 
0(1) 
1(1) 
12(1) 
-7(1) 
-10(1) 
-8(1) 
17(1) 
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Table A.5: Hydrogen coordinates ( x 104) and isotropic 
displacement parameters (Å2 x 103) for 237a. 
 x y z U(eq) 
H(2) 
H(4) 
H(4A) 
H(6A) 
H(6B) 
H(7A) 
H(7B) 
H(10A) 
H(10B) 
H(10C) 
H(11A) 
H(11B) 
H(11C) 
H(13A) 
H(13B) 
H(13C) 
H(14A) 
H(14B) 
H(15) 
H(16A) 
H(16B) 
H(17A) 
H(17B) 
H(18A) 
H(18B) 
H(18C) 
H(19A) 
H(19B) 
H(20A) 
H(20B) 
H(20C) 
H(21A) 
H(21B) 
H(22A) 
H(22B) 
H(22C) 
3136 
3204 
3239 
1273 
1933 
2296 
1491 
1486 
1703 
2281 
812 
771 
592 
2058 
2888 
2484 
2272 
2219 
1012 
1175 
453 
4183 
4971 
4972 
4826 
4195 
4656 
4678 
5700 
5823 
5673 
4054 
4733 
3996 
3896 
3332 
3121 
6403 
4211 
5604 
6631 
5892 
6309 
4852 
3225 
4424 
3650 
2914 
4553 
-1095 
-1271 
-975 
3769 
5448 
3690 
6219 
5296 
3688 
4014 
1968 
1583 
1627 
5222 
3567 
3860 
4483 
5526 
7249 
6889 
6245 
7863 
6715 
708 
2281 
2179 
1754 
1774 
935 
880 
29 
56 
142 
1291 
712 
772 
1190 
1199 
642 
2737 
2718 
2566 
3119 
3053 
310 
481 
1038 
420 
835 
2055 
1939 
1426 
2018 
1524 
1209 
869 
120 
284 
461 
18 
35 
20 
21 
21 
21 
21 
33 
33 
33 
32 
32 
32 
35 
35 
35 
22 
22 
28 
42 
42 
28 
28 
45 
45 
45 
38 
38 
68 
68 
68 
48 
48 
72 
72 
72 
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Table A.6: Torsion angles [°] for 237a. 
C(12)-C(1)-C(2)-C(3) 
C(9)-C(1)-C(2)-C(3) 
C(8)-C(1)-C(2)-C(3) 
C(1)-C(2)-C(3)-C(4) 
C(1)-C(2)-C(3)-Si(1) 
C(19)-Si(1)-C(3)-C(2) 
C(21)-Si(1)-C(3)-C(2)) 
C(17)-Si(1)-C(3)-C(2) 
C(19)-Si(1)-C(3)-C(4) 
C(21)-Si(1)-C(3)-C(4) 
C(17)-Si(1)-C(3)-C(4) 
C(2)-C(3)-C(4)-O(4) 
Si(1)-C(3)-C(4)-O(4) 
C(2)-C(3)-C(4)-C(5) 
Si(1)-C(3)-C(4)-C(5) 
O(4)-C(4)-C(5)-C(9) 
C(3)-C(4)-C(5)-C(9) 
O(4)-C(4)-C(5)-C(14) 
C(3)-C(4)-C(5)-C(14) 
O(4)-C(4)-C(5)-C(6) 
C(3)-C(4)-C(5)-C(6) 
C(9)-C(5)-C(6)-C(7) 
C(14)-C(5)-C(6)-C(7) 
C(4)-C(5)-C(6)-C(7) 
C(5)-C(6)-C(7)-C(8) 
C(6)-C(7)-C(8)-C(10) 
C(6)-C(7)-C(8)-C(11) 
C(6)-C(7)-C(8)-C(1) 
C(2)-C(1)-C(8)-C(10) 
C(12)-C(1)-C(8)-C(10) 
C(9)-C(1)-C(8)-C(10) 
C(2)-C(1)-C(8)-C(7) 
C(12)-C(1)-C(8)-C(7) 
C(9)-C(1)-C(8)-C(7) 
C(2)-C(1)-C(8)-C(11) 
C(12)-C(1)-C(8)-C(11) 
C(9)-C(1)-C(8)-C(11) 
C(14)-C(5)-C(9)-O(9) 
C(6)-C(5)-C(9)-O(9) 
C(4)-C(5)-C(9)-O(9) 
C(14)-C(5)-C(9)-C(1) 
C(6)-C(5)-C(9)-C(1) 
C(4)-C(5)-C(9)-C(1) 
C(2)-C(1)-C(9)-O(9) 
C(12)-C(1)-C(9)-O(9) 
C(8)-C(1)-C(9)-O(9) 
-141.57(18) 
-25.2(2) 
91.9(2) 
5.4(3) 
-176.40(13) 
-134.65(16) 
102.68(17) 
-14.53(17) 
43.61(17) 
-79.05(16) 
163.74(13) 
-137.59(17) 
44.17(18) 
-12.7(2) 
169.10(12) 
162.12(13) 
39.5(2) 
-77.92(17) 
159.46(15) 
44.06(18) 
-78.56(19) 
-49.37(19) 
-171.83(14) 
67.24(19) 
51.9(2) 
-174.37(14) 
66.05(18) 
-55.05(18) 
61.38(18) 
-62.05(18) 
177.13(14) 
-57.27(17) 
179.30(14) 
58.48(17) 
-177.88(14) 
58.69(18) 
-62.13(18) 
-3.2(2) 
-124.98(17) 
114.84(17) 
177.81(13) 
56.02(18) 
-64.16(17) 
-122.89(16) 
-5.9(2) 
118.70(17) 
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C(2)-C(1)-C(9)-C(5) 
C(12)-C(1)-C(9)-C(5) 
C(8)-C(1)-C(9)-C(5) 
C(2)-C(1)-C(12)-O(12) 
C(9)-C(1)-C(12)-O(12) 
C(8)-C(1)-C(12)-O(12) 
C(2)-C(1)-C(12)-O(13) 
C(9)-C(1)-C(12)-O(13) 
C(8)-C(1)-C(12)-O(13) 
O(12)-C(12)-O(13)-C(13) 
C(1)-C(12)-O(13)-C(13) 
C(9)-C(5)-C(14)-C(15) 
C(6)-C(5)-C(14)-C(15) 
C(4)-C(5)-C(14)-C(15) 
C(5)-C(14)-C(15)-C(16) 
C(19)-Si(1)-C(17)-C(18) 
C(21)-Si(1)-C(17)-C(18) 
C(3)-Si(1)-C(17)-C(18) 
C(21)-Si(1)-C(19)-C(20) 
C(17)-Si(1)-C(19)-C(20) 
C(3)-Si(1)-C(19)-C(20) 
C(19)-Si(1)-C(21)-C(22) 
C(17)-Si(1)-C(21)-C(22) 
C(3)-Si(1)-C(21)-C(22) 
 
56.15(18) 
173.12(13) 
-62.26(17) 
-135.15(18) 
109.76(19) 
-11.1(2) 
45.04(17) 
-70.04(16) 
169.12(13) 
-7.2(2) 
172.63(13) 
-67.7(2) 
53.0(2) 
175.80(16) 
-122.8(2) 
50.98(17) 
172.42(14) 
-68.23(15) 
-69.0(2) 
49.2(2) 
169.39(17) 
175.55(15) 
55.39(17) 
-63.86(17) 
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Table A.7:  Bond lengths [Å] and angles [°] for 240. 
Empirical formula 
Formula weight 
Temperature (K) 
Wavelength(Å) 
Crystal system 
Space group  
Unit cell dimensions  
a (Å)  
α (°) 
b (Å)  
β (°) 
c (Å)  
γ (°) 
Volume (Å3) 
Z 
Calculated density (Mg/m3) 
Absorption coefficient (mm–1) 
F(000)  
Crystal size (mm) 
Θ range for data collection (°) 
Limiting indices  
 
 
Reflections collected / unique  
 
Completeness to Θ= 27.46  
Absorption correction  
 
Max. transmission 
Min. transmission  
C24 H32 O4 Si 
412.59 
90.0(2)  
0.71073 
Orthorombic 
Aba2 
 
13.78770(10) 
90 
27.9022(2) 
90 
11.44220(10) 
90 
4401.90(6) 
8 
1.245 
0.134 
1776 
0.42 x 0.20 x 0.12 mm 
1.46 to 27.48 
-17≤h≤17 
-36≤k≤35 
-14≤l≤14 
4899 / 4899  
[R(int) = 0.0000] 
100.00% 
Semi-empirical from 
equivalents 
0.9841  
0.9460 
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Data / restraints / parameters  
Goodness-of-fit on F2  
Final R indices [I>2σ(I)]  
 
R indices (all data)  
 
Largest diff. peak and hole  
(e·Å–3) 
 
4899 / 1 / 267 
1.031 
R1 = 0.0317 
ωR2 = 0.0730 
R1 = 0.0380  
ωR2 = 0.0760 
.195 and -.167  
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Table A.8:  Atomic coordinates ( x 104) and equivalent 
isotropic displacement parameters (Å2 x 103) for 240. U(eq) 
is defined as one third of the trace of the orthogonalized          
Uij tensor. 
          
             x             y             z          U(eq) 
  
Si(1)     5921(1)       1399(1)       6992(1)       14(1) 
O(1)      3290(1)        190(1)       7538(1)       21(1) 
O(2)      4902(1)       2203(1)       9709(1)       24(1) 
O(3)      5757(1)       1521(1)       9596(1)       18(1) 
O(4)      3993(1)       1166(1)      10654(1)       20(1) 
C(1)      4221(1)       1496(1)       8722(1)       14(1) 
C(2)      4700(1)       1220(1)       7665(1)       14(1) 
C(3)      4705(1)        672(1)       7874(1)       15(1) 
C(4)      3689(1)        500(1)       8102(1)       16(1) 
C(5)      3156(1)        761(1)       9096(1)       16(1) 
C(6)      2271(1)       1035(1)       8577(1)       21(1) 
C(7)      2562(1)       1448(1)       7776(1)       18(1) 
C(8)      3300(1)       1796(1)       8320(1)       17(1) 
C(9)      3824(1)       1137(1)       9616(1)       15(1) 
C(10)     3581(1)       2175(1)       7406(2)       22(1) 
C(11)     2812(1)       2053(1)       9361(2)       24(1) 
C(12)     4972(1)       1794(1)       9386(1)       17(1) 
C(13)     6502(1)       1741(1)      10312(2)       23(1) 
C(14)     2797(1)        394(1)      10008(1)       20(1) 
C(15)     3576(1)         77(1)      10499(2)       21(1) 
C(16)     3598(1)       -391(1)      10353(2)       25(1) 
C(17)     6179(1)       2056(1)       7062(2)       21(1) 
C(18)     6970(1)       1051(1)       7571(1)       20(1) 
C(19)     5737(1)       1237(1)       5409(1)       18(1) 
C(20)     5374(1)       1577(1)       4613(2)       22(1) 
C(21)     5169(1)       1451(1)       3465(2)       27(1) 
C(22)     5321(1)        990(1)       3082(2)       31(1) 
C(23)     5688(1)        649(1)       3836(2)       30(1) 
C(24)     5897(1)        773(1)       4993(2)       22(1) 
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Table A.9:  Bond lengths [Å] and angles [º] for 240. 
 
Si(1)-C(18)                   1.8640(16) 
Si(1)-C(17)                   1.8681(15) 
Si(1)-C(19)                   1.8849(16) 
Si(1)-C(2)                    1.9174(15) 
O(1)-C(4)                     1.2118(19) 
O(2)-C(12)                    1.2027(19) 
O(3)-C(12)                    1.3446(18) 
O(3)-C(13)                    1.4500(18) 
O(4)-C(9)                     1.2129(19) 
C(1)-C(12)                    1.530(2) 
C(1)-C(9)                     1.534(2) 
C(1)-C(2)                     1.578(2) 
C(1)-C(8)                     1.588(2) 
C(2)-C(3)                     1.549(2) 
C(2)-H(2)                     1.0000 
C(3)-C(4)                     1.503(2) 
C(3)-H(3A)                    0.9900 
C(3)-H(3B)                    0.9900 
C(4)-C(5)                     1.538(2) 
C(5)-C(9)                     1.517(2) 
C(5)-C(14)                    1.543(2) 
C(5)-C(6)                     1.557(2) 
C(6)-C(7)                     1.526(2) 
C(6)-H(6A)                    0.9900 
C(6)-H(6B)                    0.9900 
C(7)-C(8)                     1.537(2) 
C(7)-H(7A)                    0.9900 
C(7)-H(7B)                    0.9900 
C(8)-C(10)                    1.538(2) 
C(8)-C(11)                    1.545(2) 
C(10)-H(10A)                  0.9800 
C(10)-H(10B)                  0.9800 
C(10)-H(10C)                  0.9800 
C(11)-H(11A)                  0.9800 
C(11)-H(11B)                  0.9800 
C(11)-H(11C)                  0.9800 
C(13)-H(13A)                  0.9800 
C(13)-H(13B)                  0.9800 
C(13)-H(13C)                  0.9800 
C(14)-C(15)                   1.500(2) 
C(14)-H(14A)                  0.9900 
C(14)-H(14B)                  0.9900 
C(15)-C(16)                   1.318(2) 
C(15)-H(15)                   0.9500 
C(16)-H(16A)                  0.9500 
C(16)-H(16B)                  0.9500 
C(17)-H(17A)                  0.9800 
C(17)-H(17B)                  0.9800 
C(17)-H(17C)                  0.9800 
C(18)-H(18A)                  0.9800 
C(18)-H(18B)                  0.9800 
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C(18)-H(18C)                  0.9800 
C(19)-C(24)                   1.398(2) 
C(19)-C(20)                   1.406(2) 
C(20)-C(21)                   1.389(3) 
C(20)-H(20)                   0.9500 
C(21)-C(22)                   1.375(3) 
C(21)-H(21)                   0.9500 
C(22)-C(23)                   1.380(3) 
C(22)-H(22)                   0.9500 
C(23)-C(24)                   1.398(2) 
C(23)-H(23)                   0.9500 
C(24)-H(24)                   0.9500 
C(18)-Si(1)-C(17)           110.39(7) 
C(18)-Si(1)-C(19)           108.73(7) 
C(17)-Si(1)-C(19)           107.59(8) 
C(18)-Si(1)-C(2)            113.76(7) 
C(17)-Si(1)-C(2)            113.92(7) 
C(19)-Si(1)-C(2)            101.82(7) 
C(12)-O(3)-C(13)            115.60(12) 
C(12)-C(1)-C(9)             105.31(12) 
C(12)-C(1)-C(2)             111.25(12) 
C(9)-C(1)-C(2)              110.01(11) 
C(12)-C(1)-C(8)             113.54(12) 
C(9)-C(1)-C(8)              104.59(11) 
C(2)-C(1)-C(8)              111.68(12) 
C(3)-C(2)-C(1)              111.41(12) 
C(3)-C(2)-Si(1)             108.35(10) 
C(1)-C(2)-Si(1)             123.24(10) 
C(3)-C(2)-H(2)              103.9 
C(1)-C(2)-H(2)              103.9 
Si(1)-C(2)-H(2)             103.9 
C(4)-C(3)-C(2)              109.75(12) 
C(4)-C(3)-H(3A)             109.7 
C(2)-C(3)-H(3A)             109.7 
C(4)-C(3)-H(3B)             109.7 
C(2)-C(3)-H(3B)             109.7 
H(3A)-C(3)-H(3B)            108.2 
O(1)-C(4)-C(3)              123.96(14) 
O(1)-C(4)-C(5)              121.00(14) 
C(3)-C(4)-C(5)              115.00(12) 
C(9)-C(5)-C(4)              109.09(12) 
C(9)-C(5)-C(14)             112.81(13) 
C(4)-C(5)-C(14)             109.79(12) 
C(9)-C(5)-C(6)              106.68(12) 
C(4)-C(5)-C(6)              108.97(12) 
C(14)-C(5)-C(6)             109.41(12) 
C(7)-C(6)-C(5)              113.18(12) 
C(7)-C(6)-H(6A)             108.9 
C(5)-C(6)-H(6A)             108.9 
C(7)-C(6)-H(6B)             108.9 
C(5)-C(6)-H(6B)             108.9 
H(6A)-C(6)-H(6B)            107.8 
C(6)-C(7)-C(8)              114.02(13) 
C(6)-C(7)-H(7A)             108.7 
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C(8)-C(7)-H(7A)             108.7 
C(6)-C(7)-H(7B)             108.7 
C(8)-C(7)-H(7B)             108.7 
H(7A)-C(7)-H(7B)            107.6 
C(7)-C(8)-C(10)             109.02(13) 
C(7)-C(8)-C(11)             108.53(13) 
C(10)-C(8)-C(11)            108.29(13) 
C(7)-C(8)-C(1)              108.29(12) 
C(10)-C(8)-C(1)             110.93(12) 
C(11)-C(8)-C(1)             111.72(13) 
O(4)-C(9)-C(5)              123.22(14) 
O(4)-C(9)-C(1)              122.73(14) 
C(5)-C(9)-C(1)              113.95(12) 
C(8)-C(10)-H(10A)           109.5 
C(8)-C(10)-H(10B)           109.5 
H(10A)-C(10)-H(10B)         109.5 
C(8)-C(10)-H(10C)           109.5 
H(10A)-C(10)-H(10C)         109.5 
H(10B)-C(10)-H(10C)         109.5 
C(8)-C(11)-H(11A)           109.5 
C(8)-C(11)-H(11B)           109.5 
H(11A)-C(11)-H(11B)         109.5 
C(8)-C(11)-H(11C)           109.5 
H(11A)-C(11)-H(11C)         109.5 
H(11B)-C(11)-H(11C)         109.5 
O(2)-C(12)-O(3)             123.06(14) 
O(2)-C(12)-C(1)             127.83(14) 
O(3)-C(12)-C(1)             109.09(12) 
O(3)-C(13)-H(13A)           109.5 
O(3)-C(13)-H(13B)           109.5 
H(13A)-C(13)-H(13B)         109.5 
O(3)-C(13)-H(13C)           109.5 
H(13A)-C(13)-H(13C)         109.5 
H(13B)-C(13)-H(13C)         109.5 
C(15)-C(14)-C(5)            114.54(13) 
C(15)-C(14)-H(14A)          108.6 
C(5)-C(14)-H(14A)           108.6 
C(15)-C(14)-H(14B)          108.6 
C(5)-C(14)-H(14B)           108.6 
H(14A)-C(14)-H(14B)         107.6 
C(16)-C(15)-C(14)           123.67(16) 
C(16)-C(15)-H(15)           118.2 
C(14)-C(15)-H(15)           118.2 
C(15)-C(16)-H(16A)          120.0 
C(15)-C(16)-H(16B)          120.0 
H(16A)-C(16)-H(16B)         120.0 
Si(1)-C(17)-H(17A)          109.5 
Si(1)-C(17)-H(17B)          109.5 
H(17A)-C(17)-H(17B)         109.5 
Si(1)-C(17)-H(17C)          109.5 
H(17A)-C(17)-H(17C)         109.5 
H(17B)-C(17)-H(17C)         109.5 
Si(1)-C(18)-H(18A)          109.5 
Si(1)-C(18)-H(18B)          109.5 
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H(18A)-C(18)-H(18B)         109.5 
Si(1)-C(18)-H(18C)          109.5 
H(18A)-C(18)-H(18C)         109.5 
H(18B)-C(18)-H(18C)         109.5 
C(24)-C(19)-C(20)           117.43(15) 
C(24)-C(19)-Si(1)           121.89(12) 
C(20)-C(19)-Si(1)           120.58(13) 
C(21)-C(20)-C(19)           120.97(17) 
C(21)-C(20)-H(20)           119.5 
C(19)-C(20)-H(20)           119.5 
C(22)-C(21)-C(20)           120.45(17) 
C(22)-C(21)-H(21)           119.8 
C(20)-C(21)-H(21)           119.8 
C(21)-C(22)-C(23)           120.05(16) 
C(21)-C(22)-H(22)           120.0 
C(23)-C(22)-H(22)           120.0 
C(22)-C(23)-C(24)           119.90(17) 
C(22)-C(23)-H(23)           120.1 
C(24)-C(23)-H(23)           120.1 
C(23)-C(24)-C(19)           121.19(16) 
C(23)-C(24)-H(24)           119.4 
C(19)-C(24)-H(24)           119.4 
            
 
 
 
Table A.10:  Anisotropic displacement parameters (A2 x 103) 
for 243. The anisotropic displacement factor exponent takes 
the form: -2 π2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ] 
_________________________________________________________ 
          
          U11      U22      U33      U23      U13      U12   
___________________________________________________________ 
Si(1)    15(1)    14(1)    14(1)     1(1)    1(1)     -1(1) 
O(1)     24(1)    19(1)    21(1)    -2(1)   -3(1)     -4(1) 
O(2)     29(1)    15(1)    29(1)    -6(1)   -5(1)      2(1) 
O(3)     17(1)    16(1)    20(1)    -3(1)   -6(1)     -1(1) 
O(4)     24(1)    23(1)    13(1)    -2(1)   -1(1)      2(1) 
C(1)     14(1)    13(1)    14(1)    -1(1)   -1(1)      3(1) 
C(2)     14(1)    14(1)    14(1)     0(1)   -1(1)      0(1) 
C(3)     17(1)    14(1)    15(1)    -1(1)    2(1)      0(1) 
C(4)     19(1)    13(1)    14(1)     3(1)   -2(1)      0(1) 
C(5)     14(1)    16(1)    16(1)     2(1)    0(1)     -1(1) 
C(6)     15(1)    24(1)    23(1)     2(1)   -1(1)      3(1) 
C(7)     14(1)    22(1)    18(1)     2(1)   -3(1)      4(1) 
C(8)     16(1)    17(1)    17(1)     1(1)   -2(1)      6(1) 
C(9)     14(1)    16(1)    16(1)     0(1)    1(1)      5(1) 
C(10)    23(1)    17(1)    24(1)     2(1)   -3(1)      4(1) 
C(11)    24(1)    23(1)    25(1)    -2(1)    1(1)      9(1) 
C(12)    20(1)    16(1)    14(1)     1(1)   -1(1)      0(1) 
C(13)    24(1)    23(1)    23(1)    -1(1)   -9(1)     -5(1) 
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C(14)    20(1)    21(1)    19(1)     4(1)    4(1)     -2(1) 
C(15)    24(1)    23(1)    17(1)     4(1)    0(1)     -3(1) 
C(16)    28(1)    28(1)    20(1)     3(1)    2(1)      1(1) 
C(17)    23(1)    18(1)    21(1)     1(1)    1(1)     -4(1) 
C(18)    17(1)    23(1)    20(1)     2(1)    1(1)      0(1) 
C(19)    15(1)    21(1)    17(1)     1(1)    2(1)     -3(1) 
C(20)    19(1)    26(1)    20(1)     3(1)    2(1)     -1(1) 
C(21)    19(1)    44(1)    19(1)     7(1)    0(1)      1(1) 
C(22)    19(1)    58(1)    16(1)    -9(1)    1(1)     -4(1) 
C(23)    27(1)    37(1)    26(1)   -12(1)    3(1)     -1(1) 
C(24)    19(1)    25(1)    21(1)   -2(1)     2(1)      0(1) 
___________________________________________________________ 
 
 
 
 
 
 
 
 
 
Table A.11:  Hydrogen coordinates ( x 104) and isotropic 
displacement parameters (Å2 x 103) for 240. 
___________________________________________________________ 
  
              x              y              z         U(eq) 
___________________________________________________________ 
  
H(2)         4227          1265          7011          17 
H(3A)        4972           507          7179          18 
H(3B)        5123           596          8552          18 
H(6A)        1865           807          8130          25 
H(6B)        1873          1163          9226          25 
H(7A)        1973          1630          7559          22 
H(7B)        2842          1314          7049          22 
H(10A)       2998          2347          7149          32 
H(10B)       3885          2018          6734          32 
H(10C)       4039          2403          7753          32 
H(11A)       3222          2320          9618          36 
H(11B)       2726          1826         10007          36 
H(11C)       2177          2176          9118          36 
H(13A)       6655          2060         10004          35 
H(13B)       7087          1542         10298          35 
H(13C)       6268          1771         11118          35 
H(14A)       2487           570         10659          24 
H(14B)       2295           190          9641          24 
H(15)        4081           222         10939          25 
H(16A)       3102          -546          9917          30 
H(16B)       4109          -574         10685          30 
H(17A)       6305          2149          7874          31 
H(17B)       5619          2234          6765          31 
H(17C)       6750          2129          6583          31 
H(18A)       7519          1080          7033          30 
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H(18B)       6787           713          7648          30 
H(18C)       7155          1177          8339          30 
H(20)        5269          1897          4864          26 
H(21)        4922          1685          2940          33 
H(22)        5174           906          2297          37 
H(23)        5799           331          3570          36 
H(24)        6152           537          5506          26 
         
___________________________________________________________ 
 
 
 
Table A.12:  Torsion angles [º] for 240. 
__________________________________________________________ 
  
C(12)-C(1)-C(2)-C(3)                             111.90(13) 
C(9)-C(1)-C(2)-C(3)                               -4.40(17) 
C(8)-C(1)-C(2)-C(3)                             -120.08(13) 
C(12)-C(1)-C(2)-Si(1)                            -19.50(17) 
C(9)-C(1)-C(2)-Si(1)                            -135.81(11) 
C(8)-C(1)-C(2)-Si(1)                             108.51(13) 
C(18)-Si(1)-C(2)-C(3)                            -36.23(12) 
C(17)-Si(1)-C(2)-C(3)                           -163.94(10) 
C(19)-Si(1)-C(2)-C(3)                             80.56(11) 
C(18)-Si(1)-C(2)-C(1)                             96.40(13) 
C(17)-Si(1)-C(2)-C(1)                            -31.30(14) 
C(19)-Si(1)-C(2)-C(1)                           -146.81(12) 
C(1)-C(2)-C(3)-C(4)                               55.96(16) 
Si(1)-C(2)-C(3)-C(4)                            -165.42(10) 
C(2)-C(3)-C(4)-O(1)                              123.63(16) 
C(2)-C(3)-C(4)-C(5)                              -54.20(16) 
O(1)-C(4)-C(5)-C(9)                             -178.47(13) 
C(3)-C(4)-C(5)-C(9)                               -0.56(17) 
O(1)-C(4)-C(5)-C(14)                              57.45(19) 
C(3)-C(4)-C(5)-C(14)                            -124.65(14) 
O(1)-C(4)-C(5)-C(6)                              -62.36(18) 
C(3)-C(4)-C(5)-C(6)                              115.55(14) 
C(9)-C(5)-C(6)-C(7)                               50.65(17) 
C(4)-C(5)-C(6)-C(7)                              -67.00(16) 
C(14)-C(5)-C(6)-C(7)                             172.96(13) 
C(5)-C(6)-C(7)-C(8)                              -51.44(18) 
C(6)-C(7)-C(8)-C(10)                             176.50(13) 
C(6)-C(7)-C(8)-C(11)                             -65.74(16) 
C(6)-C(7)-C(8)-C(1)                               55.71(17) 
C(12)-C(1)-C(8)-C(7)                            -174.46(13) 
C(9)-C(1)-C(8)-C(7)                              -60.18(15) 
C(2)-C(1)-C(8)-C(7)                               58.76(16) 
C(12)-C(1)-C(8)-C(10)                             65.94(17) 
C(9)-C(1)-C(8)-C(10)                            -179.78(12) 
C(2)-C(1)-C(8)-C(10)                             -60.84(16) 
C(12)-C(1)-C(8)-C(11)                            -54.99(17) 
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C(9)-C(1)-C(8)-C(11)                              59.28(15) 
C(2)-C(1)-C(8)-C(11)                             178.23(13) 
C(4)-C(5)-C(9)-O(4)                             -127.81(15) 
C(14)-C(5)-C(9)-O(4)                                -5.5(2) 
C(6)-C(5)-C(9)-O(4)                              114.62(16) 
C(4)-C(5)-C(9)-C(1)                               55.68(16) 
C(14)-C(5)-C(9)-C(1)                             177.96(12) 
___________________________________________________________ 
___________________________________________________________ 
C(6)-C(5)-C(9)-C(1)                              -61.89(15) 
C(12)-C(1)-C(9)-O(4)                              10.95(18) 
C(2)-C(1)-C(9)-O(4)                              130.92(14) 
C(8)-C(1)-C(9)-O(4)                             -109.00(16) 
C(12)-C(1)-C(9)-C(5)                            -172.52(12) 
C(2)-C(1)-C(9)-C(5)                              -52.55(16) 
C(8)-C(1)-C(9)-C(5)                               67.53(15) 
C(13)-O(3)-C(12)-O(2)                                4.0(2) 
C(13)-O(3)-C(12)-C(1)                           -174.83(13) 
C(9)-C(1)-C(12)-O(2)                            -107.17(18) 
C(2)-C(1)-C(12)-O(2)                             133.68(17) 
C(8)-C(1)-C(12)-O(2)                                 6.7(2) 
C(9)-C(1)-C(12)-O(3)                              71.58(14) 
C(2)-C(1)-C(12)-O(3)                             -47.57(16) 
C(8)-C(1)-C(12)-O(3)                            -174.57(12) 
C(9)-C(5)-C(14)-C(15)                            -66.44(17) 
C(4)-C(5)-C(14)-C(15)                             55.45(17) 
C(6)-C(5)-C(14)-C(15)                            174.99(14) 
C(5)-C(14)-C(15)-C(16)                          -116.28(18) 
C(18)-Si(1)-C(19)-C(24)                           35.50(15) 
C(17)-Si(1)-C(19)-C(24)                          155.06(13) 
C(2)-Si(1)-C(19)-C(24)                           -84.88(14) 
C(18)-Si(1)-C(19)-C(20)                         -148.32(12) 
C(17)-Si(1)-C(19)-C(20)                          -28.76(14) 
C(2)-Si(1)-C(19)-C(20)                            91.30(13) 
C(24)-C(19)-C(20)-C(21)                              1.1(2) 
Si(1)-C(19)-C(20)-C(21)                         -175.24(12) 
C(19)-C(20)-C(21)-C(22)                             -0.3(3) 
C(20)-C(21)-C(22)-C(23)                             -0.6(3) 
C(21)-C(22)-C(23)-C(24)                              0.6(3) 
C(22)-C(23)-C(24)-C(19)                              0.3(3) 
C(20)-C(19)-C(24)-C(23)                             -1.1(2) 
Si(1)-C(19)-C(24)-C(23)                          175.17(13) 
___________________________________________________________ 
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Table A.13:  Hydrogen bonds for 243 [Ǻ and º]. 
___________________________________________________________ 
  
D-H...A          d(D-H)      d(H...A)    d(D...A)    <(DHA) 
___________________________________________________________ 
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